CLINICAL STUDY PROTOCOL 
 
A Phase 2a, Randomized, Double-Blind,  Parallel-Group, Proof-of-Concept 
Study Evaluating the Sa fety, Tolerability, and Efficacy of OV101 in 
Fragile X Syndrome 
PROTOCOL NUMBER OV101-17-001 
 
Sponsor: Ovid Therapeutics Inc. 
[ADDRESS_216054]: Amit, MD, MBA Chief Medical Officer and Head of R&D 
[EMAIL_3590] 
Telephone: [PHONE_3923] 
 
Safety Monitor:  
Ovid/Sciformix 
Safety Hotline: [PHONE_3924] 
Safety Fax Line: [PHONE_3924] 
Medical Monitor: Eric J Christopher, MD, FAPA 
Associate Medical Director [COMPANY_003] 
[EMAIL_1038]  
Version of Protocol: 1.2 (Protocol Amendment 2)   
Date of Protocol: 27 Mar 2019 
CONFIDENTIAL 
All financial and nonfinancial support for this study will be provided by [CONTACT_182972]. The concepts and information contained in this document or generated during the study 
are considered proprietary and may not be di sclosed in whole or in part without the 
expressed, written consent of Ovid Therapeutics Inc. 
The study will be conducted according to the International Council for Harmonisation 
harmonised tripartite guideline E6(R2): Good Clinical Practice. 
 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216055] read and understood all sections of the protocol t itled “A Phase 2a, Randomized, 
Double-Blind, Parallel-Group, Proof-of-Concep t Study Evaluating the Safety, Tolerability, 
and Efficacy of OV101 in Fragile X Syndrome” and the accompanying investigator’s 
brochure. 
 
I agree to supervise all aspects of the protocol  and to conduct the clinical investigation in 
accordance with Final Protocol Version 1.21, dated 27 Mar 2019; the International Council 
for Harmonisation harmonised tripartite guideli ne E6(R2): Good Clinical Practice; and all 
applicable government regulations. I will not make changes to the protocol before consulting 
with Ovid Therapeutics Inc. or implement protocol changes without independent ethics 
committee approval except to eliminate an immediate risk to subjects. I agree to administer study treatment only to subjects under my personal supervision or the supervision of a sub 
investigator. 
 
I will not supply the investigational drug to any person not authorized to receive it. Confidentiality will be protected. Subject identi ty will not be disclosed to third parties or 
appear in any study reports or publications. 
 
I will not disclose information regarding this cl inical investigation or publish results of the 
investigation without authorizatio n from Ovid Therapeutics Inc. 
 
  
 
Signature [CONTACT_789]  [INVESTIGATOR_182942] r   
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 14  
 
Protocol Amendment #[ADDRESS_216056] of Abbreviations  ................................................................................................................. 28 
1 Introduction .................................................................................................................. ..... 30 
1.1 Background on Fragile X Syndrome (FXS) ...... ................................................ ...... [ADDRESS_216057] Selection and Withdrawal Criteria ......... .............................................................. 42 
4.1 Selection of Study Population ................................................................................. 42 
4.1.1 Inclusion Criteria ...................................................................................... 42 
4.1.2 Exclusion Criteria .................................................................................... 43 
4.2 Discontinuation of Subjects From Study Treatm ent and the Study ..... ............. ...... 44 
4.2.1 Reasons for Withdrawal/Discontinuation ................................................. 44 
4.2.2 Handling of Withdrawals ......................................................................... 45 
4.2.3 Replacements ........................................................................................... 46 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216058] Article Accountability  ......................................................................... 49 
5.4.3 Other Supplies .......................................................................................... 49 
5.5 Overdose Management  ............................................................................................. 50 
5.5.1 Treatment of Overdose ............................................................................. 50 
5.5.2 Medication Errors .................................................................................... 50 
5.5.3 Treatment of Medication Errors  ............................................................... 50 
5.6 Blinding ................................................................................................................... 50  
5.6.1 Breaking the Blind ................................................................................... 50 
5.7 Treatment Compliance ............................................................................................ 51 
5.8 Prior and Concomitant Therapy .............................................................................. 51 
5.8.1 Prohibited Medications and Therapi[INVESTIGATOR_014] ..................................................... 52 
5.8.2 Restrictions ............................................................................................... 52 
6 Study Assessments and Procedures .................................................................................. 53 
6.1 Study Visits ............................................................................................................. 57 
6.1.1 Screening Period  ....................................................................................... 57 
6.1.2 Baseline Visit ........................................................................................... 58 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph ............................................. 59 
6.1.3 Phone Visits to Assess Safe ty ................ ............................................. ...... 60 
6.1.4 Week 2 Clinic Visit .................................................................................. 60 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph ............................................. 61 
6.1.5 Week 6 Clinic Visit .................................................................................. 62 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph ............................................. 63 
6.1.6 End-of-Treatment Visit ............................................................................ 63 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph ............................................. 64 
6.1.7 End-of-Study Visit ................................................................................... 65 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph ............................................. 65 
6.2 Screening Assessments ............................................................................................ 66 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 16  
 6.4.1  Metabolomic Biomar kers .......................................................................... 73 
6.4.2 Cheek Microbiome Assessments .............................................................. 73 
Plasma OV101  Concentrat ions ................................................................................ 73 
[IP_ADDRESS] 
 Event Related Potential ............................................................................ 72 
6.4 
 Explorator y Laborator y Assessmen ts ...................................................................... 73 
6.5 6.2.1 Autism Spectrum Disorder ....................................................................... 66 
6.2.2 Intelligence Quotient ................................................................................ 66 
6.3 Efficacy Assessments  ............................................................................................... 66 
6.3.1 Caregiver Assessments ............................................................................. 67 
[IP_ADDRESS]  Aberrant Behavior Checklist-Community ............................................... 67 
[IP_ADDRESS]  Anxiety, Depression, and Mood Scales .................................................... 68 
[IP_ADDRESS]  Repetitive Behavior Scale-Revised ......... ................ .............. ............. ...... 68 
[IP_ADDRESS]  Conners 3rd Edition .................................................................................. 68 
[IP_ADDRESS]  Short Sensory Profile-2 ............................................................................ 68 
[IP_ADDRESS]  Children’s Sleep Habits Questionnaire .................................................... 68 
[IP_ADDRESS]  Sleep Diary ............................................................................................... 69 
[IP_ADDRESS]  Behavior Assessment System for Children, 3rd Edition ........................... 69 
[IP_ADDRESS]  Parent Global Impressions Scales ............................................................ 69 
[IP_ADDRESS] Pediatric Quality of Life Inventory .......................................................... 70 
6.3.2 Clinician Assessments .............................................................................. 70 
[IP_ADDRESS]  Structured Sleep History Form ................................................................. 70 
[IP_ADDRESS]  Pediatric Sleep Clinical Global Impressions Scales ................................. 70 
[IP_ADDRESS]  Caregiver Top 3 Concerns Visual Analog Scale ....................................... 70 
[IP_ADDRESS]  Vineland Adaptive Behavior Scale ........................................................... 71 
[IP_ADDRESS]  Clinical Global Impressions Scales .......................................................... [ADDRESS_216059] Assessments ...................................................................... 71 
[IP_ADDRESS]  Actigraphy ................................................................................................ 71 
[IP_ADDRESS]  Test of Attentional Performance for Children .......................................... 72 
[IP_ADDRESS]  Repeatable Battery for the Assessment of Neuropsychological Status .... 72 
 
 
 
6.6 Safety and Tolerability Assessments .............. ................................................ ......... 74 
6.6.1 Adverse Events ......................................................................................... 74 
[IP_ADDRESS]  Definitions of Adverse Events  .................................................................. 74 
[IP_ADDRESS]  Serious Adverse Events ............................................................................ 74 
[IP_ADDRESS]  Eliciting and Documenting Adverse Events ............................................. 75 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 17  
 [IP_ADDRESS]  Reporting Adverse Events ........................................................................ 75 
[IP_ADDRESS]  Reporting Serious Adverse Events ........................................................... 76 
[IP_ADDRESS]  Suspected Unexpected Serious Adverse Reactions .................................. 77 
[IP_ADDRESS]  Assessment of Severity ............................................................................ 78 
[IP_ADDRESS]  Assessment of Causality ........................................................................... 78 
[IP_ADDRESS]  Follow-up of Subjects Reporting Adverse Events ................................... 79 
6.6.2 Other Safety Assessments  ......................................................................... 79 
[IP_ADDRESS]  Vital Sign Measurements ......................................................................... [ADDRESS_216060] Assessment Endpoints ...................................................... 84 
7.5 Sample Size Calculations  ......................................................................................... 84 
7.6 Analysis Sets ........................................................................................................... 85 
7.7 Description of Subgroups to be Analyzed ............................................................... 86 
7.8 Statistical Analysis Methodology ............................................................................ 86 7.8.1 Safety Analyses ........................................................................................ 87 
7.8.2 Analysis of Secondary Efficacy Endpoints .............................................. 88 
7.8.3 Analyses of Exploratory Endpoints ......................................................... 88 
7.8.5 Exploratory Modelling ............................................................................. 89 
7.8.6 Other Analyses ......................................................................................... 89 
[IP_ADDRESS]  Demographics and Other Baseline Character istics .................................. 89 
Anal yses of Other Ex plorator y Endpoints ............................................... 88 
 7.8.4 
Othe r Explorator y Endpoints ................................................................................... 84 
 7.4 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 18  
 [IP_ADDRESS]  Drug Treatments ....................................................................................... [ADDRESS_216061](s) ... ........................................................................ ...... [ADDRESS_216062] Information and Consent ............................................................................ 93 
10 Investigator’s Obligations ................................................................................................. [ADDRESS_216063] ......................................................................................................... 96 
10.5 Adherence to Protocol ............................................................................................. 96 
10.6 Adverse Events and Study Report Requirements .................................................... 97 
10.7 Investigator’s Final Report ...................................................................................... [ADDRESS_216064] ................................................................................................................ .. 101 
13 Appendix (Israel Site-Specific Instructions) ....... ............................................................. 105 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216065] of Figures 
Figure 1–1 Main Sites of Action of OV101, Benzodiazepi[INVESTIGATOR_050], and Novel Benzodiazepi[INVESTIGATOR_050]- 
Like Compounds ............................................................................................. 33 
 
Figure 3–1 Study Schematic .............................................................................................. 39 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 20  
 Protocol Synopsis 
 
Protocol Number: 
OV101-17-001 
Title: 
A Phase 2a Randomized, Double-Blind, Parall el Group, Proof-of-Concept Study Evaluating 
the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome 
Sponsor: 
Ovid Therapeutics Inc. 
[ADDRESS_216066] 
[LOCATION_001], NY [ZIP_CODE] 
Study Phase: 
Phase 2a 
Study Sites: 
Approximately 8 sites in the [LOCATION_002] and approximately 1 site in Israel 
Indication: 
Fragile X syndrome 
Rationale: 
Ovid Therapeutics Inc. is developi[INVESTIGATOR_55597]101 (g aboxadol) for the treatment of rare genetic 
disorders that are associated with severe deve lopmental and behavioral challenges, such as 
Angelman syndrome and Fragile X syndrome (F XS). Gaboxadol was initially developed for 
the treatment of insomnia by H. Lundbeck  A/S and [COMPANY_006], but its development was 
discontinued in 2007 for clinical and commercia l reasons. Extensive nonclinical and clinical 
data were generated during the initial stages of development, including data from exposure to 
gaboxadol in more than 4300 adult subjects with insomnia and approximately 500 adult 
subjects in non–insomnia-related studies. 
Fragile X syndrome is the most common inheri ted form of intellectual disability, with a 
prevalence of [ADDRESS_216067] common known 
genetic cause of autism; approximately 25% to 30% of individuals with FXS meet the full 
diagnostic criteria for autism, and approximatel y 5% of children with autism carry the fragile 
X mutation. Males with FXS have moderate to severe intellectual disability, and females with 
FXS range from normal to moderate impairment. 
Individuals with FXS are at increased risk for a range of behavioral problems that may limit 
their academic performance, adaptive function, daily living skills, and social interactions. Anxiety is the most common behavioral problem in individuals with FXS, with specific 
symptoms of shyness, social anxiety, hypera rousal, and stereotypic behavior such as hand 
flappi[INVESTIGATOR_182943]. Aggressive behavior s in male individuals with FXS are also 
common and may lead to injuries to care givers, peers, or friends. Attention- 
deficit/hyperactivity disorder symptoms (ove rarousal, hyperactivity, distractibility, and 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 21  
 impulsivity) may also be noted. Individuals wi th FXS can experience problems in one or 
more of these behavior domains. There is a wide range of variability in symptoms, although 
they tend to be more severe in males than in females. 
Current behavior therapy treatments include spee ch therapy, physical therapy, occupational 
therapy, and educational resources. Current treatments with medications target only the 
behavioral phenotypes and not the underlying brain deficits. 
OV101 is the first highly selective, extr asynaptic gamma-aminobutyric acid (GABA) 
receptor agonist that binds as an orthosteric agonist to the α4- and δ-containing subunit of 
extrasynaptic GABA receptors. The mech anism of action of OV101 is unique among 
GABAergic agents, including benzodiazepi[INVESTIGATOR_1651], zolpi[INVESTIGATOR_182944]-like drugs, 
neurosteroids, and drugs that ac t on GABA metabolism or uptake. 
The use of OV101 for treatment of individuals with FXS is based on studies in a relevant mouse model of the disease, the Fmr1 knockout (KO) mouse, which lacks the fragile X 
mental retardation protein due to a disruption in its FMR1 gene. Fmr1 KO mice have 
decreased GABA synthesis, decreased pr esynaptic GABA releas e, and decreased 
extrasynaptic levels of GABA, resulting in de creased tonic inhibition. OV101 was shown to 
restore tonic inhibition in the amygdala, reduce sensory hypersensitivity and motor hyperactivity, and improve pre-pulse inhibition (signal to noise ratio) in Fmr1 KO mice. 
Cogram et al recently presented data that showed full normalization of abnormal repetitive, 
social, and anxiety-like behaviors with OV101 in another FXS KO mouse model, the Fmr1 
KO2 mouse. Taken together, th ese data support the potential of OV101 to treat the core 
behavioral deficits noted in individuals wi th FXS. Importantly, th e ability of OV101 to 
potentiate tonic inhibition is unlike any other GABAergic agent, including benzodiazepi[INVESTIGATOR_1651], 
zolpi[INVESTIGATOR_6730], other zolpi[INVESTIGATOR_6730]-like drugs, neurosteroid s, and drugs that act on GABA metabolism 
or uptake. 
Phase 2 and Phase 3 studies in adult subjects  with primary insomnia demonstrated that 
OV101 is effective in restoring classical sl eep parameters (sleep induction and sleep 
maintenance) and slow wave sleep, resulting in an improvement in the quality and restorative 
effects of sleep. 
The purpose of this study is to investigate the safety, tolerability, and ex ploratory efficacy of 
treatment by [CONTACT_182973]101 at doses of 5 mg/day (5 mg once a day [QD]), 
10 mg/day (5 mg twice a day [BID]), or 15 mg/day (5 mg three times a day [TID]) in 
adolescent and adult male subjects with FX S. The 12-week, randomized, double-blind, 
parallel-group, proof-of-concept study design will inform OV101 clinical development and 
the design of future studies in FXS. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 22  
  
Objectives: 
Primary Objectives: 
 To evaluate the safety and tolerability of OV101 over 12 weeks of treatment across 
different daily dosing regimens in adolescent and adult male subjects with FXS 
Secondary Objectives: 
 To evaluate changes in behavior during 12 weeks of treatment with OV101 across different daily dosing regimens in adolescent and adult male subjects with FXS 
Exploratory Objectives : 
 To evaluate changes in sleep, adaptive functioning, and quality of life across different 
daily dosing regimens of OV101 treatment over 12 weeks in adolescent and adult male subjects with FXS 
 To evaluate possible acute rebound phenom ena (eg, sleep disruption or behavioral 
problems) that occur following disconti nuation of treatment with OV101 using 
outcome assessments administered at a follow-up visit 4 to 6 weeks after the end of 
treatment 
 To explore the relationships among pl asma levels of OV101, metabolomic 
biomarkers, and treatment response 
 To explore the relationships among subjects’ microbiomes and clinical presentation of FXS or treatment response 
 To explore the relationships between event related potential meas urements and levels 
of OV101 or treatment response 
 To explore the relationships among study endpoints (eg, behavior, sleep), where 
appropriate 
 To obtain plasma OV101 concentrations for use in combination with data from other studies to perform population PK and PK-pharmacodynamic (PD) analysis and to 
evaluate the exposure-response of OV101 in individuals with FXS 
Study Population: 
Inclusion criteria: 
1. Is male and 13 to 22 years old (inclusive) at the time of informed consent.   
2. Has a diagnosis of FXS with a confirmed FMR1 full mutation ( ≥200 CGG repeats). 
The diagnosis must be confirmed by [CONTACT_182974]. 
3. Has a Clinical Global Impression-Severity score of 4 (moderately ill) or greater at 
screening. 
4. Is currently being treated with no more than 3 anti-epi[INVESTIGATOR_55607]/or psychoactive 
medications, including those prescribed o ff-label to address behavioral conditions. 
Any concomitant medication, including anti-e pi[INVESTIGATOR_55607]/or behavioral medications, 
supplements, and special diets,  must be at a stable dose for at least [ADDRESS_216068] be maintained at that dose throughout the duration of the 
study. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 23  
 5. Has a legally acceptable representative (LAR)/caregiver capable of providing 
informed consent and able to attend all scheduled study visits, oversee the 
administration of study drug, and provide fe edback regarding the subject’s behavior 
and other symptoms as described in the protocol. 
6. Provide assent to the protocol (to the extent possible and in accordance with local institutional review board and regulatory requirements) and have an LAR/caregiver 
who will provide written informed consent. Subjects providing assent must do so at 
the same visit as LAR/caregiver wri tten informed consent is provided. 
7. Is able to attend all scheduled study visits  and willing and capable of performing the 
required study assessments. 
8. Is able to ingest the study drug capsules (including sprinkling capsule contents onto 
1 spoon of applesauce or low-fat yogurt). 
9. Has an intelligence quotient less than [ADDRESS_216069] dose of study treatment. 
11. Has LAR/caregivers who will agree not to po st any of the subject’s personal medical 
data related to the study or information related to the study on any website or social media site (eg, Facebook and Twitter) until they have been  notified that the study is 
completed. 
Exclusion criteria: 
1. Has a concomitant disease (eg, gastrointestinal , renal, hepatic, endocrine, respi[INVESTIGATOR_696], 
or cardiovascular system disease) or conditi on or any clinically significant finding at 
screening that could interfere with the conduct of the study or that would pose an unacceptable risk to the subject in this study. 
2. Has clinically significant lab abnormalities or  vital signs at the time of screening (eg, 
alanine aminotransferase or aspartate amin otransferase >2.5 × upper limit of normal; 
total bilirubin or creatinine >1.5 × upper lim it of normal). Re-testing of safety labs 
may be allowed after consultation with the medical monitor or designee. 
3. Uses any GABAergic agent (eg, acampros ate, baclofen, vigabatrin, tiagabine, 
riluzole, benzodiazepi[INVESTIGATOR_1651], and gabapent in) when used on a regular schedule. 
Benzodiazepi[INVESTIGATOR_182945] l anxiety (eg, for occasional procedures 
or events) are permitted. 
4. Uses any cannabinoid derivatives. 
5. Has a history of uncontrollable seizure diso rder or seizure epi[INVESTIGATOR_42988] [ADDRESS_216070] 3 months. 
6. Has a history of suicidal behavior or consider ed by [CONTACT_182975]. 
7. Has any condition or there is any reason that, in the opi[INVESTIGATOR_871], makes 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216071] an LAR/caregiver able to comply with study requirements. 
9. Has enrolled in any clinical trial or used of any investigational agent, device, and/or 
investigational procedure within the 30 days before screening or does so concurrently 
with this study. 
10. Is a family member of the investigator or study site personnel. 
Study Design: 
This is a Phase 2a, randomized, double-blind, parallel-group study to evaluate the safety, 
tolerability, and efficacy of OV101 at 3 daily doses: 5 mg/day (5 mg QD), 10 mg/day (5 mg 
BID), and 15 mg/day (5 mg TID) in adolescent and adult male subjects with FXS. Subjects with a clinically and molecularly confirmed diagno sis of FXS will be eligible for inclusion in 
the study. The study will comprise a screening period of at least 1 week (to allow for 
actigraphs) and up to 3 weeks; a baseline  visit on Day 1 for treatment randomization 
(enrollment), baseline assessments, and first dose of study drug; clinic visits for safety and 
efficacy assessments over a 12-week treatment period, including clinic visits at Week 2, 
Week 6, and Week 12 (end-of-treatment [EOT ]); and an end-of-study (EOS) follow-up visit 
occurring any time between the ends of Week [ADDRESS_216072], after informed consent is obtained, screening assessments will be 
completed within the 3 weeks preceding Baseline. At Baseline, subjects 13 to 22 years old 
(inclusive) who meet all eligibility criteria will be enrolled on Day 1 in a 1:1 target ratio 
between adolescents (13 to17 years old, inclusive) and adults (18 to 22 years old, inclusive). A sufficient number of subjects will be enrolled to ensure that at least 30 evaluable subjects 
complete 12 weeks of treatment. 
Subjects will be randomly assigned in a 1:1:1 ra tio to 1 of 3 treatment groups (5 mg QD, 5 
mg BID, and 5 mg TID), stratified by [CONTACT_182976] (adolescent/adult) to achieve balance among 
treatment arms. All subjects will take stu dy drug TID (morning, afternoon, and evening), 
OV101 in the morning and OV101 or placebo in the afternoon and evening throughout the 
treatment period (including Baseline). There wi ll not be any dose adjustments permitted 
during the study. 
After random assignment at Baseline, subjects will receive the assigned package of blinded 
study treatment according to the treatment code for the first [ADDRESS_216073] dose of study drug at the clinic. They will receive another assigned package of 
study treatment at the Week 6 clinic visit. 
Subjects (assisted by [CONTACT_182977]/care givers) will complete paper sleep diaries and wear actigraphs 
over the 7-day periods immediately preceding Ba seline and the Week 2, Week 6, EOT, and 
EOS clinic visits. The Baseline, Week 2, Week 6, and EOT visits will be full-day clinic visits. 
Safety information will be collected during phon e calls at the end of Weeks 1, 4, 8, and 10 
(on Days 8, 29, 57, and 71, respectively), in ad dition to during every clinic visit (screening, 
Day 1, Week 2, Week 6, EOT, and EOS). At the investigator’s discretion, subjects may be 
evaluated at unscheduled clinic visits for reasons related to subject safety. At unscheduled 
visits, subjects will be queried about AEs,  changes in concomitant medications, and 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 25  
  
suicidality, and safety laborat ory assessments may be conducted. Periodic interim blinded 
review of safety data will be performed as  part of routine pharmacovigilance activities. 
Estimated Study Duration: 
After informed consent is obtained, screeni ng assessments will be conducted within the 
[ADDRESS_216074] participation of 
21 weeks. 
Efficacy Assessments: 
Efficacy assessments will include the Aberrant Behavior Checklist–Community; the Anxiety, 
Depression, and Mood Scales; the Repetitive Behavior Scale–Revised; the Conners3rd 
Edition; the Short Sensory Profile–2; the Pe diatric Sleep Clinical Global Impressions 
(Severity and Improvement) scales; Children’s  Sleep Habits Questionnaire; a 7-day sleep 
diary; the Behavior Assessment System for Children, 3rd Edition Parenti ng Relationship 
Questionnaire; Parent Global Impressions (Sev erity and Improvement) scales; the Pediatric 
Quality of Life Inventory; a top 3 concerns visual analog scale; the Vineland Adaptive 
Behavior Scale–3rd Edition; Clinical Global Impression s (Severity and Improvement) scales; 
7-day actigraphy; a computerized measurement of cognition using the Test of Attentional 
Performance for Children; the Repeatable Batter y for the Assessment of Neuropsychological 
Status; and an optional event related potential. 
Pharmacokinetic Assessments: 
Blood samples will be collected for the determ ination of plasma OV101 concentrations at 
Baseline and Weeks 2, 6, and EOT at the following time points: 
 One PK sample collected between 0.5 and 0.75 hours postdose 
 One PK sample collected between 3 and 4 hours postdose 
Plasma OV101 concentration data obtained from this study may be combined with data from 
prior studies to perform population PK and PK-PD analyses and to evaluate the exposure- 
response of OV101 in individuals with FXS. Th e results of these analyses will be reported 
separately from the clinical study report for this study. 
Safety Assessments: 
All subjects who receive study drug will be ev aluated for study drug safety and tolerability. 
Assessments will include: frequency and severi ty of treatment-emergent adverse events 
(TEAEs) and serious adverse events (including TEAEs leading to discontinuation), 
standardized clinical assessment of suicidality,  clinical laboratory evaluations, and vital sign 
measurements. 
Study Drug, Dosage, and Route of Administration: 
Subjects will be assigned to receive 1 of 3 daily doses of OV101: 5 mg/day, 10 mg/day, or 
15 mg/day. Subjects will take all doses orally (assisted by [CONTACT_182978]/care giver, if necessary), 
TID (morning, afternoon, evening) at approximately the same tim es each day, for the 
duration of the 12-week treatment period. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 26  
  
OV101 Treatment Group Morning Dose Afternoon Dose Evening Dose 
5 mg/day 5-mg OV101 capsule Placebo capsule Placebo capsule 
10 mg/day 5-mg OV101 capsule Placebo capsule 5-mg OV101 capsule 
15 mg/day 5-mg OV101 capsule 5-mg OV101 capsule 5-mg OV101 capsule 
The morning and afternoon doses should be taken with food, and the afternoon dose should 
be taken at least 6 hours after the morni ng dose. The evening dose should be taken 
30 minutes before bedtime. Capsules may be  opened and the contents sprinkled onto 
1 teaspoon of low-fat semi-liquid food (eg, applesauce, yogurt, pudding) for ingestion, but this approach must be followed consistently th roughout the study. The capsule contents must 
not be placed directly in liquid. The LAR/caregiver must document specifically how each 
capsule was taken (eg, swallowed whole or taken in 1 teaspoon of food). 
Placebo capsules will be identical in appearance to the capsules containing OV101 and have 
the same excipi[INVESTIGATOR_182946]101. Study drug will be supplied as 
5-mg capsules of OV101 and matching place bo capsules in bottles. Bottles will have 
“Morning,” “Afternoon,” or “Evening” printed on their labels. Each LAR/caregiver will 
receive a 6-week supply of capsules in  a package containing 1 “Morning” bottle, 
1 “Afternoon” bottle, and 1 “Evening” bottle at the baseline (Day 1) visit and at the Week 6 
visit. 
Sample Size : 
A sufficient number of subjects (36 estimated) will be enrolled to ensure that 30 evaluable 
subjects complete 12 weeks of treatment. Subj ects will be randomly assigned to the 3 OV101 
total daily dosing regimens in a 1:1:1 ratio. 
The main emphasis in reporting the data will be  on descriptive statistics and estimation with 
95% CIs. For the objective of estimating the overall subject incidence of TEAEs (for the 
3 OV101 total daily dose arms combined), a true  incidence of 20% would be estimated with 
a 13.9% precision (half-width of the 2-sided 95% CI assuming N = 30). 
Analysis Sets: 
The randomized analysis set will be used for summaries of subject disposition, 
demographics, and other baseline characteristics.  The safety analysis set (all subjects who 
receive at least 1 dose of study drug) will be used for the analysis of all safety parameters, 
analyzed according to treatment received. The full analysis set (all subjects who receive at least [ADDRESS_216075] 1 postbaseline efficacy evaluation) will be used 
for analysis of all efficacy parameters, analyzed according to randomized treatment. The modified full analysis set may be used for exploratory modelling of selected efficacy variables, in addition to the full analysis set. 
Statistical Methods: 
Descriptive statistics (number of subjects, mean, SD, median, minimum, and maximum) will 
be presented for continuous variables and thei r changes from baseline. In addition, 95% CIs 
for the mean change from baseline will be provided for continuous variables. Graphical 
displays will be utilized to investigate trends  over time and dose and the relationship between 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 27  
  
certain variables and differences between age groups. 
Ordinal variables with sufficient numerical cate gories (eg, 7-point scales of Parent Global 
Impressions-Severity and Clinical Global Impressions-Severity) and subscale total scores 
from questionnaires will be tr eated as continuous variables. 
Categorical (not treated as continuous) endpo ints (including adverse event incidence and 
binary endpoints) will be summarized by [CONTACT_7237]. Frequencies and 
percentages will be presented for the shifts in  these categories (eg, low to normal, low to 
high, high to low) from baseline to each post-tr eatment assessment time point for scales with 
categorical variables. If there are missing values, the number missing will be presented (as a category), but without a percentage. All data co llected will be included in by-subject data 
listings. 
All adverse events will be coded using Medical Dictionary  for Regulatory Activities 
(MedDRA) and will be classified by [CONTACT_11189] (SOC) and preferred term 
(PT). The number and percentage  of subjects who experience at least1 TEAE and the number 
and percentage of subjects who experience at least 1 TEAE within each specific SOC and PT 
will be presented by [CONTACT_182979]. The number of TEAEs (event 
incidence) will also be summarized within each SOC and PT. The Wilson 95% CIs will be 
displayed for the proportion of subjects experiencing TEAEs as a total across the [ADDRESS_216076]-hoc exploratory modelling may be conducted on selected 
variables using the full analysis set (and modified full analysis set, as required). 
Individual plasma OV101 concentrations will be listed, plotted, and summarized in the same 
way as other continuous endpoints (number of subjects, mean, SD, median, minimum, and 
maximum). 
Graphical displays (eg, scatter plots of PK concentrations versus PD response) may be 
generated to better understand the OV101 PK-PD profile. 
Version and Date of Protocol: 
Version 1.2, 27 March 2019 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216077] Edition 
CSHQ Children’s Sleep Habits Questionnaire 
CSR clinical study report 
DSM-5 Diagnostic and Statistical Manual of Mental Disorders 
eCRF electronic case report form 
EDC electronic data capture 
EEG 
EOS electroencephalography end of study 
EOT end of treatment 
ERP event related potential 
FAS full-analysis set 
FDA US Food and Drug Administration 
FMRP fragile X mental retardation protein 
FXS fragile X syndrome 
GABA gamma-aminobutyric acid 
GCP Good Clinical Practice 
ICF informed consent form 
ICH International Council for Harmonisation 
IQ intelligence quotient 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216078] of Attentional Performance for Children 
KO Knockout 
LAR legally acceptable representative 
MedDRA Medical Dictionary for Regulatory Activities 
mFAS modified full-analysis set 
MMRM Mixed Model with Repeated Measures 
PD pharmacodynamic(s) 
PedsQL Pediatric Quality of Life Inventory 
PGI-I Parent Global Impressions-Improvement 
PGI-S Parent Global Impressions-Severity 
P
K pharmacokinetic(s) 
PT preferred term 
QD once a day 
RBANS Repeatable Battery for the Asse ssment of Neuropsychological Status 
RBS-R Repetitive Beha vior Scale-Revised 
SAE serious adverse event 
SB-[ADDRESS_216079] Edition 
WASO 
WISC 
WPPSI wake time after sleep onset 
Wechsler Intelligence Scale for Children 
Wechsler Preschool and Primary Scale of Intelligence 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 30  
  
1 Introduction 
Ovid Therapeutics Inc. (Ovid) is developi[INVESTIGATOR_55597]101 (gaboxadol) for the treatment of rare 
genetic disorders that are associated with se vere developmental and behavioral challenges, 
such as Angelman syndrome (AS) and Fragile  X syndrome (FXS). Gaboxadol was initially 
developed for the treatment of insomnia by H. Lundbeck A/S and [COMPANY_006], but its development 
was discontinued in 2007 for clinical and comm ercial reasons. Extensive nonclinical and 
clinical data were generated during the initia l stages of development by [CONTACT_42039]/[COMPANY_006], 
including data from exposure to gaboxadol in more than 4300 adult subjects with insomnia 
and approximately 500 adult subjects in non–insomnia-related studies. Details of the 
Lundbeck/[COMPANY_006] program, including both the nonclinical program and the clinical program, are found in the investigator’s brochure (Ovid Therapeutics Inc. 2017). Unless otherwise 
indicated, the source for the information in this  introduction is the investigator’s brochure. 
 
1.1 Background on Fragile X Syndrome (FXS) 
Fragile X syndrome is the most common inherited form of intellectual disability, with a 
prevalence of 1 in 4000 males and 1 in 8000 fema les (Crawford et al 2001). It is also the 
most common known genetic cause of autism; approximately 25% to 30% of individuals with FXS meet the full diagnostic criteria for autism, and approximately 5% of children with 
autism carry the fragile X mutation (Hall et al  2008; Harris et al 2008). Males with FXS have 
moderate to severe intellectual disability , and females with FX S range from normal to 
moderate impairment (Hagerman et al 2010). 
 
The primary molecular basis underlying FXS is a reduced expression level or lack of fragile 
X mental retardation protein (FMRP). Reduced or absent FM RP is most commonly caused 
by [CONTACT_182980]-guanine-guanine (CGG) repeats in the 
5’ untranslated region of FMR1 on the X chromosome. The increased number of CGG 
repeats results in hypermethylation of DNA regions where a cytosine nucleotide is followed 
by a guanine nucleotide, which ultimately prevents transcription and leads to either partial or full silencing of gene expression. The full mu tation, defined as over [ADDRESS_216080] to the full 
mutation, the premutation (defined as 55 to 200 CGG repeats) leads to enhanced production 
of FMR1 messenger RNA (mRNA; 2 to 8 times the normal levels) (Kenneson et al 2001). 
Enhanced mRNA production can lead to clinical  features in premutation carriers that do not 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 31  
 occur in individuals with full mutation FXS, including fragile X–associated primary ovarian 
insufficiency and fragile X −associated tremor/ataxia syndrome (Tassone et al 2000). 
 
Understanding the effects of the fragile X mu tation on brain development and function has 
been facilitated by [CONTACT_182981][INVESTIGATOR_182947]. The best established animal model is the Fmr1 knockout (KO) mouse 
(Bakker et al 1994). An RNA-binding protein,  FMRP modulates the dendritic localization 
and translation of several hundred mRNA ligands (Fernández et al 2013). In the FMR1 KO 
mouse, the absence of FMRP leads to excessive  protein synthesis downstream of signaling 
pathways coupled to group I metabotropic gl utamate receptors (mGluRs), in particular 
mGluR5. Inhibition of mGluR5 and downstream signaling has been shown to correct a wide array of disease phenotypes in animal models  of FXS (Bhakar et al 2012). Glutamatergic 
transmission is under tight regulation by [CONTACT_182982] a-aminobutyric acid ( GABA)-ergic inhibition, 
and deficiencies in GABA-mediated inhibitory ne urotransmission have been identified in the 
hippocampus, striatum, somatose nsory cortex, and amygdala of Fmr1 KO mice (D’Hulst and 
Kooy 2007). The most consistent  neurochemical change in the Fmr1 KO mouse is impaired 
GABAergic neurotransmission, and this dysfunc tion has been implicated in many of the 
symptoms of FXS, including anxiety, au tism-like behavior, epi[INVESTIGATOR_002], and cognitive 
impairment. Specifically , GABAergic tonic inhibition is believed to underlie many of these 
symptoms and may, therefore, be an effective novel target for therapeutic treatment of FXS 
(Gantois et al 2006; Olmos-Serrano et al 20 10; Martin et al 2014). Use of GABA agonists 
has been suggested as a therap eutic strategy for FXS (Olmos-Serrano et al 2010; Braat and 
Kooy 2015). 
 
1.[ADDRESS_216081] common behavioral problem in individuals with FXS, with specific 
symptoms of shyness, social anxiety, hyperarousal, and stereotypic behavior such as hand flappi[INVESTIGATOR_182943]. Aggressive behavior s in male individuals with FXS are also 
common and may lead to injuries  to caregivers, peers, or friends (Wheeler et al 2016). 
Attention-deficit/hyperactivity disorder symptoms  (overarousal, hyperact ivity, distractibility, 
and impulsivity) may also be noted. Individuals with FXS can experience  problems in one or 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 32  
 more of these behavior domains. There is a wide range of variability in symptoms, although 
they tend to be more severe in males than in females (Hagerman 2002). 
 
Disordered sleep is a phenotype noted in animal models of FXS, and pa rents typi[INVESTIGATOR_182948] (Zhang et al 2008). Studies have estimated that 
31% to 77% of individuals with FXS have sleep problems (Kronk et al 2010). Children with 
FXS typi[INVESTIGATOR_182949], more difficulties settling into sleep, and 
increased wake time after sleep onset (WASO) than unaffected children (Gould et al 2000; 
Richdale 2003). 
 
Current behavior therapy treatments include sp eech therapy, physical  therapy, occupational 
therapy, and educational resources. Current treatments with medications target only the 
behavioral phenotypes and not the underl ying brain deficits (Hagerman et al 2009). 
 
1.3 Background on OV101 
OV101 (gaboxadol) or 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridin-3-ol (THIP) was 
synthesized in the late 1970s and has since been used in nonclinical studies as a GABA A 
receptor agonist. More than [ADDRESS_216082] to the α4- and δ -containing subunit of 
extrasynaptic GABA receptors (Figure 1–1). 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 33  
 
The investi gator’s brochure contains furthe r information on the nonclinical pharmacolo gy 
and toxicolo gy of OV101 (Ovid Thera peutics Inc. 2017 ). Figure 1–1 Main Sites of Action of OV101, Benzodiazepi[INVESTIGATOR_050], and Novel 
Benzodiazepi[INVESTIGATOR_050]-Like Compounds 
 
 
Abbreviations: BZD, benzodiazepi[INVESTIGATOR_182950]-like compounds; GABA, gamma-aminobutyric acid; 
GBX, OV101 (gaboxadol). 
 
 
The affinity of OV101 is [ADDRESS_216083] 
benzodiazepi[INVESTIGATOR_182951]-like compounds  (eg, zolpi[INVESTIGATOR_6730]). In vitro binding studies 
have shown that gaboxadol binds selectively to the extrasynaptic α4δ-containing GABA A 
receptor subpopulation and possesses no significant affinities for other target receptors in the 
central and peripheral nervous system. Conversely, the presence of α4 or δ subunits in the 
GABA receptor confers insensitivity to benzodiazepi[INVESTIGATOR_1651]. The mechanism of action of OV101 is unique among GABAergic agents, including  benzodiazepi[INVESTIGATOR_1651], zolpi[INVESTIGATOR_182952]-like drugs, neurosteroids, and dr ugs that act on GABA metabolism or uptake. 
In vivo and in vitro studies have shown that neither benzodiazepi[INVESTIGATOR_182953]101, and in contrast to be nzodiazepi[INVESTIGATOR_182954], no withdrawal 
effects were observed in animals after chronic dosing with OV101. In drug discrimination 
studies, rats and baboons trained to respond to benzodiazepi[INVESTIGATOR_182955]101. 
Furthermore, OV101 did not show abuse potential in baboons trained to self-inject cocaine. 
 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 34  
 1.4 Clinical Experience with OV101 
OV101 was generally safe and well  tolerated in all Phase 2 and 3 studies that included more 
than 4300 subjects with insomnia (aged 18 to  64 years) who were administered doses up to 
15 mg (20 mg in one early Phase 2 study). In adult subjects, the most common adverse 
events (AEs) that occurred more frequently in OV101-treated subjects than in subjects on 
placebo were dizziness, nausea, vomiting, somnolence, and headache. Most AEs were of 
mild to moderate intensity. Generally, tolerabili ty was better in male subjects than in female 
subjects, most likely due to the lower body weight of females. 
 
OV101 administration in the morning was safe at all doses (Study [ZIP_CODE]). In healthy young 
men, doses up to [ADDRESS_216084] incidences in this study were dizz iness, nausea, headache, and somnolence. The 
majority of AEs had a rapid onset (within 1 to  2 hours postdose) and resolved after the drug 
was discontinued. 
 
Safety data from Study [ZIP_CODE] showed that 30 mg and 45 mg OV101 in women and 45 mg OV101 in men was not tolerated based on their history of hypnotic/sedative abuse or other 
drug abuse. This is contrary to previous  experience with the same doses in healthy 
volunteers. These findings suggest that a history of hypnotic/sedative abuse or other drug 
abuse decreases the tolerability of supratherape utic doses of gaboxadol. Adverse events that 
were associated with lack of tolerability included psychiatric events such as agitation, dissociation, hallucinations, disorientation, and anxiety. 
 
Approximately 500 subjects were exposed to OV101 in clinical studies in 
non−insomnia -related development. The safety and tolerability profile of OV101 in the 
non−insomnia -related studies was similar to that in sl eep disorder studies. In general, the 
AEs were dose related, with no AEs reported at the 5-mg dose and only mild AEs reported 
for the 10-mg dose of OV101. 
 
Phase 2 and Phase 3 studies in adult subjects with primary insomnia demonstrated that 
OV101 is effective in restoring classical sl eep parameters (sleep induction and sleep 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 35  
 1.5 Pharmacokinetics in adults and adolescents 
The pharmacokinetic (PK) profile of OV101 was similar re gardless of whethe r it was 
administered in the mornin g or evenin g in the fastin g state (Study [ZIP_CODE] ). There were also no 
differences between mornin g and evenin g PK when OV101 was given with food. A hi gh-fat 
meal just before OV101 administration in the mornin g or evenin g dela yed absor ption by 0.5 
to 1 hours and decreased the maximum concentration b y approximatel y 30% com pared to the 
fastin g state, whereas ex posure was practicall y unchan ged. 
In adults, OV101 was ra pi[INVESTIGATOR_182956] y at doses of [ADDRESS_216085], with elderl y people 
havin g higher exposure and sli ghtly longer elimination half-lives than younger adults. No maintenance) and slow wave sleep, resulting in an improvement in the quality and restorative 
effects of sleep (Roth et al 2010). 
 
Currently, OV101 is being investigated by [CONTACT_182983]. Results from 
Study OV101-16-[ADDRESS_216086] experienced 2 nonserious AEs (flushing, considered to be related to study drug, and injection site bruising, considered to be unrelated to study drug) that were mild in intensity. 
 
OV101 has been studied in a 12-week Phase 2 safety and efficacy study in 88 subjects (adults and adolescents aged 13 to 49 years) with AS. Fifty-eight subjects were treated with 
OV101 either once-daily (15 mg at bedtime) or twice-daily (10 mg in the morning, 15 mg 
at bedtime), and 29 patients were treated with placebo. Treatment discontinuations due to AEs were low (placebo, 1; OV101 once-daily, 0; OV101 twice-daily, 3). The most frequent 
AEs across all treatment groups were vomiting,  somnolence, irritability, aggression, pyrexia, 
and upper respi[INVESTIGATOR_4416]. The AEs associ ated with OV101 treatment were similar to 
placebo treatment, with the majority of AEs bei ng mild. Events occurring in >5% (2 or more 
patients) compared to placebo in either treatment arm included pyrexia, rash, seizure, enuresis, and myoclonic epi[INVESTIGATOR_002]. Two subjects had a SAE of seizure, both of whom had a 
previous history of seizures: [ADDRESS_216087] in th e once-daily dose group, deemed unrelated to 
study drug, and treatment was continued; [ADDRESS_216088] in the twice-daily dose group, deemed as 
possibly related to study drug, and treatment was discontinued. Please see the investigator 
brochure for additional information on the study in AS and the benefit risk profile. 
 
 
 
 
 
 
 
 
 
 
 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216089] was observed when 
OV101 was co-administered with alcohol. In the adolescent (13-17 years) PK stud y 
(OV101-16-001 ) with sub jects with FXS o r AS, the P K profile of a sin gle 5 m g dose of 
OV101 a ppeared com parable to tha t of young adults in the Lundbeck/[COMPANY_006] studies.  
 
 
 
 
 
 
1.6 Study Rationale and the Role of GABA in FXS 
There is a high unmet medical need for effective therapi[INVESTIGATOR_182957]. Current approaches to psychopharmacological treatment (eg, stimulants, mood stabilizers, and anxiolytics) for FXS are symp tom targeted to manage difficult behaviors 
without regard to the underlying pathophysiology. There is currently no drug approved for the treatment of FXS. 
 
The use of OV101 for treatment of individuals with FXS is based on studies in a relevant 
mouse model of the disease, the Fmr1 KO mouse, which lacks FMRP due to a disruption in 
its FMR1 gene. Fmr1 KO mice have decreased GABA s ynthesis, decreased presynaptic 
GABA release, and decreased extrasynaptic levels of GABA, resulting in decreased tonic inhibition. OV101 was shown to restore tonic inhibition in the amygd ala, reduce sensory 
hypersensitivity and motor hyperactivity, and improve pre-pulse inhibition (signal to noise 
ratio) in Fmr1 KO mice (Olmos-Serrano et al 2010; Olmos-Serrano et al 2011; Martin et al 
2014). Cogram et al recently presented data that showed full normalization of abnormal repetitive, social, and anxiety-like behaviors with OV101 in another FXS KO mouse model, 
the Fmr1 KO2 mouse (Cogram et al 2017). Taken together, these data support the potential 
of OV101 to treat the core behavioral deficits noted in individuals with FXS. Importantly, the 
ability of OV101 to potentiate tonic inhibition is unlike any other GABAergic agent, including benzodiazepi[INVESTIGATOR_1651], zolpi[INVESTIGATOR_6730], other zo lpi[INVESTIGATOR_6730]-like drugs, neurosteroids, and drugs 
that act on GABA metabolism or uptake. 
 
In addition to these data on presynaptic dysfunc tion, additional studies support the potential 
of OV101 in FXS. Chronic treatment in mice re sulted in both an increase in hippocampal 
neurogenesis and improved performance in se veral cognitive tasks (Whissell et al 2013). 
Moreover, OV101 has shown anticonvulsant/anti-epi[INVESTIGATOR_182958] 
(Kristensen et al 2003; Sun et al 2013; Medrihan et al 2015). accumulation was evident afte r [ADDRESS_216090] exclusively 
eliminated via the urine, mainl y as the unchan ged dru g. No clinicall y relevant interactions 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 37  
 This study will enroll only male subjects with FXS. FXS is more common in males, and 
males are more severely affected than females (likely because females have an additional X chromosome). Thus, the FXS phenotype in male subjects is expected to be more 
homogeneous than in female subjects, thus leading to a more homogeneous treatment 
response in this early Phase 2 study than would be likely if both male and female subjects 
were enrolled. 
 
The purpose of this study is to investigate the safety, tolerability, and ex ploratory efficacy of 
treatment by [CONTACT_182973]101 at doses of 5 mg/day (5 mg once a day [QD]), 
10 mg/day (5 mg twice a day [BID]), or 15 mg/day (5 mg three times a day [TID]) in 
adolescent and adult male subjects with FX S. The 12-week, randomized, double-blind, 
parallel-group, proof-of-concept study design will inform OV101 clinical development and 
the design of future studies in FXS. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 38  
 
biomarkers, and treatment res ponse 
FXS or treatment res ponse 
levels of OV101 o r treatment res ponse 
studies to perform population P K and PK- pharmacod ynamic (PD) anal ysis and to 
evaluate the ex posure-res ponse of OV101 in individuals with FXS 2 Study Objectives 
2.1 Primary Objectives 
 To evaluate the safety and tolerability of OV101 over 12 weeks of treatment across 
different daily dosing regimens in adolescent and adult male subjects with FXS 
 
2.2 Secondary Objectives 
 To evaluate changes in behavior during 12 weeks of treatment with OV101 across 
different daily dosing regimens in adolescent and adult male subjects with FXS 
 
2.3 Exploratory Objectives 
 To evaluate changes in sleep, adaptive func tioning, and quality of life across different 
daily dosing regimens of OV101 treatment over 12 weeks in adolescent and adult 
male subjects with FXS 
 
 



 


 


 


 To explore the relationships among study endpoints (eg, behavior, sleep), where 
appropriate 
 
 


To obtain plasma OV101 concentrations for use in combination with data from other 
To ex plore the relationshi ps between event related potential (ERP) measurements and 
To ex plore the relationshi ps amon g subjects’ microbiomes and clinical presentation of 
To ex plore the relationshi ps amon g plasma levels of OV101, metabolomic To eva luate poss ible acute re bound phenomena (eg, sleep disrupt ion or behavioral 
problems) that occur following discont inuation of treatment w ith OV101  using  
outcome assessments a dministere d at a follow-up v isit 4 to 6 weeks after the end of 
treatment  
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 39  
 3 Investigational Plan 
3.1 Study Design 
This is a Phase 2a, randomized, double-blind, parallel-group study to evaluate the safety, 
tolerability, and efficacy of OV101 at 3 daily doses: 5 mg/day (5 mg QD), 10 mg/day (5 mg BID), and 15 mg/day (5 mg TID) in adolescen t and adult male subjects with FXS. Subjects 
with a clinically and molecularly confirmed diagnosis of FXS will be eligible for inclusion in the study (Section 4.1). The study will comprise a screening period of at least 1 week (to 
allow for actigraphs) and up to 3 weeks; a baseline visit on Day 1 for treatment 
randomization (enrollment), baseline assessments,  and first dose of study drug; clinic visits 
for safety and efficacy assessments over a 12-week treatment period, including clinic visits at Week 2, Week 6, and Week 12 (end-of-treatme nt [EOT]); and an end-of-study (EOS) follow- 
up visit occurring any time between the ends of Week 16 and Week 18 (Figure 3–1). The schedule of activities for this study is fully presented in Table 6-1. 
 
Figure 3–1 Study Schematic 
 
 
 
 
 
 
 
Abbreviations: AM, morning dose only; BID, twice a day; EOS, end of study; EOT, end of treatment; TID, 
3 times a day. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216091], after informed consent is obt ained (Section 9.3), scr eening assessments will 
be completed within the 3 weeks preceding Baseline. At Baseline, subjects 13 to 22 years old 
(inclusive) who meet all eligibility criteria (S ection 4.1) will be enrolled on Day 1 in a 1:1 
target ratio between adolescents (13 to17 years ol d, inclusive) and adults (18 to 22 years old, 
inclusive). A sufficient number of subjects will be enrolled to ensure that at least 30 evaluable 
subjects complete 12 weeks of treatment. 
 
Subjects will be randomly assi gned in a 1:1:1 ratio to 1 of 3 treatment groups (5 mg QD, 
5 mg BID, and 5 mg TID), stratified by [CONTACT_551] (adolescent/adult) to achieve balance 
among treatment arms. There is no placebo group in this study. All subjects will take study 
drug TID (morning, afternoon, and evening), OV101 in the morning and OV101 or placebo 
in the afternoon and evening throughout the treatment period (including Baseline), as described in Section 5.[ADDRESS_216092] (assisted by a legally acceptable representative [LAR]/caregiver) will complete paper sleep diaries and wear actigraphs ov er the 7-day periods immediately preceding 
Baseline and the Week 2, Week 6, EOT, a nd EOS clinic visits. The Baseline, Week 2, 
Week 6, and EOT visits will be full-day clinic visits. 
 
For each subject, after informed consent is obtained, the maximum duration of individual subject participation will be [ADDRESS_216093] visit (includes follow-up visit). 
 
Safety information will be collected during phone calls at the end of Weeks 1, 4, 8, and 10 
(on Days 8, 29, 57, and 71, respectively), in a ddition to during every clinic visit (screening, 
baseline, Week 2, Week 6, EOT, and EOS). At the investigat or’s discretion, subjects may be 
evaluated at unscheduled clinic visits for reas ons related to subject safety. At unscheduled 
visits, subjects will be queried about AEs, changes in concomita nt medications, and 
suicidality, and safety laboratory assessments  may be conducted. Periodic interim blinded 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216094] in the absence of detectable plasma concentrations. review of safety data will be performed as part of routine pharmacovigilance activities. No 
interim statistical analysis is planned. 
 
Activities during each period of the study are described by [CONTACT_182984] 6.1 and are 
presented in greater detail in the workbooks  for caregiver/clinician/subject assessments. 
 
3.1.1 Rationale of Dose Selection 
The total daily doses to be administered in  the present study range from 5 mg/day to 
15 mg/day, which are within the dose range previously found to be well tolerated in adult 
subjects. 
 
 
Therefore, OV101 exposure in the presen t study in adolescent male subjects is 
expected to be comparable to the exposure range previously studied across the Phase 1, 2, 
and 3 studies that evaluated OV101 in adult subjects with insomnia.   
 
Daily doses of 5 mg/day, 10 mg/day, and 15 mg/day will be evaluated with 3 dosing regimens: OV101 5 mg QD (morning), BID, and TID. 
 
 
 
After the last dose of study drug during the tr eatment period (at the EO T clinic visit) there 
will be no tapering of OV101 dosing, as no  withdrawal effects have been observed in 
previous clinical studies.  Results from Study OV101 -16-001 indicate t hat the PK profile of OV101  following 
administration of a single 5 mg ora l dose to a dolescent (13- to 17-year-o ld) male and female 
subjects w ith FXS or AS is compara ble to t he PK profile prev iously observe d in healthy adult 
subjects.  
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216095] meet all of the following criteria to be enrolled in this study. 
 
1. Is male and 13 to 22 years old (inclusive) at the time of informed consent. 
2. Has a diagnosis of FXS with a confirmed FMR1 full mutation ( ≥200 CGG repeats). 
The diagnosis must be confirmed by [CONTACT_182974]. 
3. Has a Clinical Global Impression-Severity (CGI-S) score of 4 (moderately ill) or greater at screening. 
4. Is currently being treated with no more than 3 anti-epi[INVESTIGATOR_55607]/or psychoactive 
medications, including those prescribed of f-label to address behavioral conditions. 
Any concomitant medication, including anti- epi[INVESTIGATOR_55607]/or behavioral medications, 
supplements, and special diets, must be at  a stable dose for at least [ADDRESS_216096] be maintained at that  dose throughout the duration of the study. 
5. Has an LAR/caregiver capable of providing informed consent and able to attend all 
scheduled study visits, oversee the administra tion of study drug, and provide feedback 
regarding the subject’s behavior and other symptoms as described in the protocol. 
6. Provide assent to the protocol (to the extent possible and in accordance with local institutional review board [IRB] and re gulatory requirements) and have an 
LAR/caregiver who will provide written informed consent. Subjects providing assent must do so at the same visit as LAR/caregiver written informed consent is provided. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216097] the study drug capsules (including sprinkling capsule contents onto 
1 spoon of applesauce or low-fat yogurt). 
9. Has an intelligence quotient (IQ) less than [ADDRESS_216098]-Binet-5 (SB-5) at screening or a previously docu mented SB-[ADDRESS_216099] dose of study treatment. 
11. Has LAR/caregivers who will agree not to post any of the subject’s personal medical 
data related to the study or information rela ted to the study on any website or social 
media site (eg, Facebook and Twitter) until they have been notified that the study is 
completed. 
4.1.2 Exclusion Criteria 
Subjects meeting any of the following criteria will be excluded from the study: 
 
1. Has a concomitant disease (eg, gastrointestin al, renal, hepatic, endocrine, respi[INVESTIGATOR_696], 
or cardiovascular system disease) or condi tion or any clinically significant finding at 
screening that could interfere with the conduct of the study or that would pose an 
unacceptable risk to the subject in this study. 
2. Has clinically significant lab abnormalities or vital signs at the time of screening (eg, alanine aminotransferase or aspartate aminot ransferase >2.5 × upper limit of normal; 
total bilirubin or creatinine >1.5 × upper li mit of normal). Re-testing of safety labs 
may be allowed after consultation with the medical monitor or designee. 
3. Uses any GABAergic agent (eg, acamprosate,  baclofen, vigabatrin, tiagabine, riluzole, 
benzodiazepi[INVESTIGATOR_1651], and gabapentin) on a regular schedule. Benzodiazepi[INVESTIGATOR_182959] (eg, for occasional procedures or events) are permitted. 
4. Uses any cannabinoid derivatives. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216100] an LAR/caregiver able to comply with study requirements. 
9. Has enrolled in any clinical trial or used  any investigational agent, device, and/or 
investigational procedure within the [ADDRESS_216101] from treatment early (before Week 12) for any reason will 
initiate procedures for discontinuation of the subject from the study, including EOT and EOS 
visits (Section 3.1). For subjects for whom study treatment is stopped early (before Week 12), 
an EOT visit should be conducted within [ADDRESS_216102] as the date 
signed written informed consent is  provided through the EOS visit. 
 
4.2.1 Reasons for Withdrawal/Discontinuation 
Subjects may withdraw from the study at any time and for any reason without prejudice to 
their future medical care by [CONTACT_160511]. Study drug administration may be stopped early at the discretion of the in vestigator (or designee) if a subject does not 
tolerate the dosing regimen. Every effort should be made to keep subjec ts in the study. The 
reasons for subjects not continuing in the study will be recorded. A subject may be withdrawn from the study for any of the following reasons: 
 
1. The subject does not meet the protocol inclusion or exclusion criteria. 
2. The subject has a serious or intolerable AE that, in the investigator’s opi[INVESTIGATOR_1649], requires withdrawal from the study. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216103] has symptoms (or an intercurrent illness) that are not consistent with the 
protocol requirements or that justify withdrawal. 
5. The subject is lost to follow-up. 
6. Other reasons (eg, development of contraindications to use of study drug). 
7. The subject (or his LAR/caregiver) withdraws assent (consent) or the investigator or 
sponsor decides to discontinue the subject’s participation in the study. 
The investigator will also withdraw a subject if Ovid terminates the study. Upon occurrence 
of a serious or intolerable AE, the investigator  will confer with the medical monitor and/or 
sponsor. If a subject is discontinued because of an AE, the event will be followed until it is resolved. Any subject may withdraw his or her consent at any time. 
 
4.2.[ADDRESS_216104] withdraws from the study treatment or active participation in the study, the reason(s) for withdrawal shall be reco rded by [CONTACT_182985] (eCRF) us ing the electronic data capture (EDC) system. 
Whenever possible, all subjects who stop st udy treatment or withdraw from the study 
prematurely will complete the EOT and EOS a ssessments. Subjects who fail to return for 
final assessments will be contact[CONTACT_63819] s ite (2 documented phone calls followed by 1 
registered letter, as applicable) in an atte mpt to have them comply with the protocol. 
 
It is vital to obtain follow-up data on any subject withdrawn or  who withdraws because of an 
AE or serious AE (SAE). In every case, efforts must be made to undertake protocol-specified 
safety follow-up procedures. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216105] 30 evaluable subjects 
complete 12 weeks of treatment. 
 
Subjects who fail to satisfy all inclusion and exclusion criteria at screening may be 
rescreened 1 additional time at the discre tion of the medical monitor or his designee. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 47  
 5 Study Treatments 
5.1 Method of Assigning Subjects to Treatment Groups 
Subjects who meet all eligibility criteria will be randomly assigned at Baseline to the 
5 mg/day, 10 mg/day, or 15 mg/day OV101 treatment group in a 1:1:1 allocation ratio. It is 
anticipated that approximately 36 male subjec ts will be enrolled (to obtain 30 evaluable 
subjects), while maintaining a 1:1 target ratio between adolescents (13 to17 years old, inclusive) and adults (18 to 22 years old,  inclusive). The randomization schedule will be 
stratified by [CONTACT_654] (13 to 17, inclusive; 18 to 22, in clusive). It will also use an appropriate block 
size, which will not be revealed. 
 
An interactive web response system (IWRS) will be used to administer the randomization schedule. The [COMPANY_003] Biostatistics group will ge nerate the randomization schedule using SAS
® 
software (SAS Institute Inc, Cary, NC) Version 9. [ADDRESS_216106] 
randomization numbers to treatment codes.   
 
5.2 Treatments Administered 
Subjects will take all doses oral ly (assisted by [CONTACT_182978]/caregiver,  if necessary) TID (morning, 
afternoon, evening), at approximately the same times each day, for the duration of the 
12-week treatment period. The morning and afternoon doses should be ta ken with light low- 
fat food (a glass of low-fat milk would qual ify as food), and the afternoon dose should be 
taken at least 6 hours after the morning dose . The evening dose should be taken 30 minutes 
before bedtime. Capsules may be opened and the contents sprinkled onto 1 teaspoon of low- 
fat semiliquid food (eg, applesauce, yogurt, puddi ng) for ingestion, but this approach must be 
followed consistently throughout the study. The capsule contents must not be placed directly 
in liquid. The LAR/caregiver must document specifically how each capsule was taken (eg, 
swallowed whole or taken in 1 teaspoon of semiliquid food). 
 
5.3 Description of Study Drug 
OV101 is formulated as the monohydrate form (4,5,6,7-tetrahydro-isoxazolo[5,4-c]-pyridin- 3-ol, monohydrate) in a white size 2 capsule. The capsule contains 5.645 mg of OV101 monohydrate, which corresponds to 5.0 mg of OV101 (Table 5-1). 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 48  
 o 
y r  
  
 
 Component   Function   Amount (mg) 
 OV101a   Active compound   5.[ADDRESS_216107]-gelatin capsu le
a Delivered as the zwitt e
1.129 g of the zwitteri o 
rion mon 
n monoh  – 
hydrate. One gram of th 
drate.  
e anhydrous f  [ADDRESS_216108] “Morning,” “Afternoon ,” or “Evening” printed on their labels, 
which will be tinted specific colors for the morning, afternoon, and evening doses. Each 
LAR/caregiver will receive a 6-week supply of capsules in a package containing 
1 “Morning” bottle, 1 “Afternoon” bottle, and 1 “Evening” bottle at the baseline visit and at 
the Week 6 visit. 
 
Study drug will be packaged to enable administration for each treatment group regimen 
(Table 5-2). 
Pharmaceutical Com position of OV101 for the 5-m g Capsule 
 Table 5-1 
Yourwa y Trans port 
Yourwa y Trans port (Allentown, 
PA). Yourwa y Trans port 
Metrics Contract Services (Greenville, NC ) 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 49  
 Table 5-2 Treatment Group Regimens 
 
Treatment Group Morning Dose Afternoon Dose Evening Dose 
5 mg/day OV101 5-mg OV 101 capsule Placebo capsule Placebo capsule 
10 mg/day OV101 5-mg OV101 capsule Placebo capsule 5-mg OV101 capsule 
15 mg/day OV101 5-mg OV101 capsule 5-mg OV101 capsule 5-mg OV101 capsule 
 
 
A clinical label will be affixed to the outside of each bottle and each package of 3 bottles. 
The label will specify the sponsor name (Ovid Therapeutics Inc.); subject number; protocol 
number; bottle number (based on randomizat ion); number of capsules (each bottle); 
“Morning,” “Afternoon,” or “Evening”; and “Take as directed.” Bottles and study treatment will be distributed by [CONTACT_182986], and bottle quantities will be supplied to each study center in accordance with the 
IWRS. The recommended storage conditions and e xpi[INVESTIGATOR_5695] (where required) will be stated 
on the product label. At the study site, study dr ug must be stored in a secure area (eg, a 
locked cabinet), protected from moisture, and kept  at a controlled room temperature, 59°F to 
77°F. 
 
Subjects and LAR/caregivers  must keep all study drugs in the original bottles. 
 
5.4.[ADDRESS_216109] also be recorded. At the completion of the study, to satisfy regulatory requirements regarding drug accounta bility, all study drug will be reconciled and 
retained or destroyed accordi ng to applicable regulations.   
 
5.4.3 Other Supplies 
Actigraphs  
 
Section [IP_ADDRESS]) will be supplied to study sites by [CONTACT_50213][INVESTIGATOR_130747] (Murrysville, PA). Philips Resp ironics Inc will be responsible for device 
maintenance during the study and device retrieval at the end of the study. 
(Phili ps Actiwatches; 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216110] be promptly reported to the Ovid/Sciformix Safety Hotline (Section [IP_ADDRESS]). Overdoses 
without signs or symptoms do not need to be recorded as AEs; any AEs associated with the 
overdose should be reported on the rele vant AE/SAE sections in the eCRF. 
 
5.5.[ADDRESS_216111]’s clinical status. 
 
5.5.2 Medication Errors 
A medication diary will be maintained by [CONTACT_55639]/caregiver on behalf of the subject for the duration of the treatment period to confirm dosing dates and times and to permit monitoring for medication compliance and medication errors . The medication diary will be reviewed at 
each clinic visit by [CONTACT_182987]. If a dose is missed, 
this should be noted and the dose should not be doubled at the next scheduled dose. 
 
5.5.[ADDRESS_216112] likely symptomatic medication error will be overdose (Section 5.5.1). 
 
5.6 Blinding 
The study will be performed in a double-blind manner, with the subjects, LAR/caregivers, 
investigators, study personnel, monitors, and st udy sponsor blinded to th e identity of all study 
drug. All study drug will be supplied in identical packaging and will be similar in color, 
smell, taste, and appearance to enable double-blind conditions. 
 
5.6.[ADDRESS_216113]’s treatment assignment will not be brok en until after the last  subject has completed 
the study and the database has been locked, unl ess medical treatment of the subject depends 
on knowing the study treatment the subject received. In the event that the blind needs to be 
broken because of a medical emergency, the investigator may unblind an individual subject’s 
treatment allocation. Before unblinding a subject’s treatment assignment and as soon as 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216114]’s 
treatment is unblinded, the sponsor must be notified immediately. 
 
5.[ADDRESS_216115] ed by [CONTACT_182988] (labeled “Morning,” 
“Afternoon,” or “Evening”). The LAR/caregiver will be questioned as to the reason(s) why 
remaining capsules have not been administered (eg, forgot, subject refused, subject had side effects so parent decided to give a drug holi day), and the approximate  date and time of any 
missed doses will be recorded in the eCRF. 
 
5.8 Prior and Concomitant Therapy 
Subjects should be on stable doses of pres cribed medications and on stable nonmedication 
interventions (eg, speech therapy, physical ther apy, occupational therapy) for [ADDRESS_216116]’s eCRF. The minimum 
requirement is that drug name [CONTACT_183022]. Concomitant 
medications include all prescription drugs, herbal products, vitamins, minerals, and 
over-the-counter medications. Any changes in conc omitant medications will also be recorded 
in the subject’s eCRF. 
 
Any concomitant medication deemed necessar y for the welfare of the subject during the 
study may be given at the discretion of the inves tigator. However, it is the responsibility of 
the investigator to ensure that details regarding the medication are recorded in full in the 
eCRF. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 52  
 5.8.1 Prohibited Medicati ons and Therapi[INVESTIGATOR_55606] (eg, acamprosat e, baclofen, vigabatrin, tiagabine, riluzole, 
benzodiazepi[INVESTIGATOR_1651], and gabapentin) on a regular sc hedule is prohibited from the time informed 
consent is obtained to the end of a subject’s participation in the study. 
 
Use of cannabinoid derivatives is prohibited during the course of the study. 
Use of other investigational agents is pr ohibited during the course of the study. 
5.8.2 Restrictions 
Any concomitant medication, including anti-e pi[INVESTIGATOR_55607]/or behavioral medications, 
supplements, and special diets, must be at a st able dose for at least [ADDRESS_216117] may be treated concurrently w ith no more than 3 anti-epi[INVESTIGATOR_55607]/or 
psychoactive medications, including those pr escribed off-label to address behavioral 
conditions. 
 
Benzodiazepi[INVESTIGATOR_182960] (eg, for occasional procedures or 
events) are permitted. Subjects should not consume alcohol during the course of the study. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216118] of study assessme nts and procedures will be provided in the 
workbooks for caregiver/clin ician/subject assessments. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 54  
 Table 6-1 Schedule of Activities by [CONTACT_182989] 1 Week 2 Phone 4 Week 6 Phone 8 Phone 10 EOT EOS 
Window (days) –a – ±2 ±3 ±2 ±3 ±2 ±2 ±3 +14 
Dayb –21 to 1 1 8 15 29 43 57 71 85 113 
Week – 0 1 2 4 6 8 10 12 16c 
Obtain informed consent and assent X          
Verify inclusion/exclusion criteria X X         
Obtain medical history X Xd         
Conduct clinical assessmente for FXS X          
Stanford-Binet-5 or previous SB-5 documentationf X          
Review for DSM-5 autism spectrum disorder 
criteria X          
Molecular FXS Testg X          
PK sampling  X  X  X   X  
 
 X    X   X   Biomarke r assessment (plasma, cheek swab;  
 optional)  
Clinical assessment of suicidality X X X X X X X X X X 
Physical examination X Xd  X  X   X X 
Vital signs X X  X  X   X X 
Clinical laboratory tests X Xd  X  X   X  
Randomization assignment  X         
Adverse event inquiry X X X X X X X X X X 
Concomitant medication inquiry X Xd X X X X X X X X 
Dispense medication diary  X    X     
Review/collect medication diary, assess compliance    X  X   X  
Dispense study drug  X    X     
Collect unused study drug      X   X  

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 55  
  
Visit Name [CONTACT_183023] 1 Week 2 Phone 4 Week 6 Phone 8 Phone 10 EOT EOS 
Window (days) –a – ±2 ±3 ±2 ±3 ±2 ±2 ±3 +14 
Dayb –21 to 1 1 8 15 29 43 57 71 85 113 
Week – [ADDRESS_216119] Edition X (LF) X (SF)  X (SF)  X (SF)   X (SF) X (SF) 
Short Sensory Profile-2  X  X  X   X X 
Children’s Sleep Habits Questionnaire  X  X  X   X X 
Sleep diary issuedh X X  X  X   X  
Sleep diary collected and reviewed  X  X  X   X X 
BASC-[ADDRESS_216120] Edition  X    X   X  
CGI- Severity X X  X  X   X X 
CGI- Improvement    X  X   X X 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 27 Mar 2019 
Page 56  
  
Visit Name [CONTACT_183023] 1 Week 2 Phone 4 Week 6 Phone 8 Phone 10 EOT EOS 
Window (days) –a – ±2 ±3 ±2 ±3 ±2 ±2 ±3 +14 
Dayb –21 to 1 1 8 15 29 43 57 71 85 113 
Week – [ADDRESS_216121]-Completed  Measures            
Actigraph issued X X  X  X   X  
Actigraph and actigraphy data collectedk  X  X  X   X X 
KiTAP X X    X   X X 
RBANS X X    X   X X 
Event related potential (optional)  X    X   X  
Abbreviations: BASC-3, Behavior As sessment System for Children, 3rd Edition; CGI, clinical global impressions; DSM-V, Diagnostic and Statistical Manual of Mental Disorders; 
EOS, end of study; EOT, end of treatment; FXS, fragile X syndrome; KiTAP, Test of At tentional Performance for Children; LF, lon g form; PK, pharmacokinetic; RBANS, 
Repeatable Battery for the Assessment of  Neuropsychological Status; SF, short form. 
Note: At the investigator’s discretion, subjects may be evaluate d at unscheduled clinic visits for reasons related to subject s afety. At unscheduled visits, subjects will be queried 
about AEs, changes in concomitant medications, and suicida lity, and safety laboratory assessments may be conducted. 
a Screening is to be conducted for up to 21 days (inclusive) before Day 1; subjects who meet all en try criteria can be randomly a ssigned at any time during the screening period. 
b There is no Day 0. The screening period can start up to 21 days before Day 1. 
c The EOS visit may occur 4 to 6 weeks after the EOT visit, betwee n the end of Week 16 and the end of Week 18 for subjects who do  not stop treatment early. 
d If the screening and baseline visits can be completed within 10 da ys, the following procedures do not need to be repeated at th e baseline visit: medi cal history, physical 
examination, clinical laboratory tests and determination of concomitant medications. 
e Signs and symptoms of FXS. 
f For the site in Israel, please see Appendix for site-specific details regarding the IQ test. 
g Only if no written evidence for molecular dia gnosis is available in the subject’s records. 
h The sleep diary is to be completed over the 7-day periods immediately preceding Day 1 and the Week 2, Week 6, EOT, and EOS clin ic visits; a calendar will be issued to 
ensure that the diary information collection starts on the appropriate days. 
i At the initial screening visit, the clinician will complete parts A, B, and C of the structured sleep history form. 
j At clinic visits after the screening visit, the clinician will complete only part A of the structured sleep history form. 
k The actigraph is to be worn and actigraphy data are to be collec ted for the 7-day periods immediately preceding Day 1 and the W eek 2, Week 6, EOT, and EOS clinic visits; a 
calendar will be issued to ensure that the subject starts wearing the actigraph on the appropriate days. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216122] will be scheduled for 5 clinic visits and 4 phone 
visits (Table 6-1). At the investigator’s discre tion, subjects may be evaluated at unscheduled 
clinic visits for reasons related to subject safety. At unscheduled visits, subjects will be queried about AEs, changes in concomitant medications, and suicidality, and safety 
laboratory assessments may be conducted. 
 
6.1.[ADDRESS_216123] dose will be administered. Subjects who meet all entry criteria can be randomly assigned at any time during the screening period. 
 
Written informed consent (from the subject’s LAR/caregiver) and assent (from the subject) will be obtained before the subject participat es in any study procedure and begins the study 
screening procedures for eligibility. Assent will be  obtained if the investigator believes that 
the subject can provide it (depending on the subj ect’s intellectual ability), but assent may not 
be relevant based on the subject’s intell ectual disability and/or age (Section 9.3). 
 
During the screening period, the investigator will determine whether the LAR/caregiver and 
subject are able to complete all questionnaires and assessments that require their 
contributions and will also assess their ability to comply with study procedures. Screening of 
siblings will require approval from the medical monitor or his designee. 
 
For those subjects without doc umentation of a molecularly confirmed diagnosis of FXS, 
blood samples will be obtained during the sc reening period to confirm the molecular 
diagnosis of FXS. 
 
In preparation for participation in this trial, LAR/caregivers will be educated on the clinical 
safety data for OV101 obtained thus far and will  be trained to report efficacy assessments and 
to identify, manage, and report any potential AEs. 
 
The LAR/caregiver will be provided with a sleep diary for documenting the subject’s sleep 
and 1 wearable actigraph (Section 6.3.3) to docu ment daily and nocturnal activities and sleep 
pattern. The subject will wear the actigraphy device and the LAR/caregiver will record data 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 58  
 
ERP (if applicable consent provided ). in the sleep diary for at least [ADDRESS_216124] (Section 4.2.3). 
 
If a screening test result (laboratory or any othe r test) is considered uncertain or abnormal, 
the test may be repeated to confirm the resu lt after approval from the medical monitor. 
 
6.1.2 Baseline Visit 
Screened subjects will return to the study center for the baseline (Day 1) visit. The LAR/caregiver will bring the subject’s complete d sleep diary and actigraph, and study staff 
will manage the sleep diaries and actigraphs duri ng the visit as detailed in Section [IP_ADDRESS]. 
Prior to randomized assignment of study regimen, study center staff must confirm 
appropriate completion of the sleep diary, proper recording of the actigraph, and fulfilment of 
all eligibility criteria (Section 4.1). 
 
Subjects who meet all eligibility criteria will be randomly assigned to treatment at Baseline 
as described in Section 5.1. After assignment at Baseline, subjects/caregivers will receive the 
IWRS-assigned package of blinded study treatm ent according to the treatment code for the 
first 6 weeks of treatment. 
 
The following schedule of activities should be observed for subjects at the baseline visit: 
 
1. Subject should eat a light low-fat breakfast (eg , cereal with low-fat milk, bagel 
with low-fat cream cheese, low-fat yogurt) before coming to the clinic. 
 
2. Study staff conduct the following assessments that involve subject participation, in the following order: Test of Attentiona l Performance for Children (KiTAP),  
Repeatable Battery for the Assessment of  Neuropsychological Status (RBANS), and 
 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 59  
 
completed consent ) 
laborator y tests (Section 6.9 ) are performed. 3. Morning dose is administered in the clinic (s tudy staff will record time and date). On 
all clinic visit days, the morning dose must be administered before noon. 
 
4.  
 
 
5. Subject optionally eats a light low-fat snack.   
 
6.  
 
Subject vital sign measurements, urine sampling, 
can be completed at any time during the visit. The LAR/caregiver 
questionnaires and investigator/study staff qu eries of the LAR/caregiver concerning AEs, 
concomitant medications, and subject suicidalit y (Section 6.8) can also be completed at any 
time during the visit.   
 
The subject and his LAR/caregiver will be expected to complete the Baseline dosing 
(afternoon and evening doses) and continue st udy drug administration for the remainder of 
the study. 
 
Details of the order of activities and instructions for assessments are provided in the 
workbooks for caregiver/clin ician/subject assessments. 
 
Screening and baseline assessmen ts must be performed within a 21-day period. If the 
screening and baseline visits can be completed within 10 days, the following assessments do 
not need to be repeated at the baseline visit: medical history, physical examination, clinical 
laboratory tests, and determinati on of concomitan t medications. 
 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph 
[IP_ADDRESS].[ADDRESS_216125] the LAR/caregiver in the proper use of the sleep diary. 
and cheek swab (if applicable based on 
At 3 to 4 hours postdose, PK blood sam pling is performed. 
At 0.5 to 0.75 hours postdose, P K blood sam pling and blood sam pling for clinical 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 60  
 A new sleep diary will be issued to the LAR/ca regiver for use in the 7-day period preceding 
the Week 2 clinic visit. A calendar reminder will also be provided for the start of sleep diary 
assessments. 
 
[IP_ADDRESS].[ADDRESS_216126]’s actigraph as described in the study manual and will review the quality of the data. If quality issues are detected, study staff will review 
proper use of the actigraph with the LAR/caregi ver. Study staff will issue a fully charged, 
reset actigraph to the LAR/caregiver, includi ng new hospi[INVESTIGATOR_182961] (if needed; Section 6.3.3), 
for use in the 7-day period preceding the Week 2 clinic visit. A calendar reminder will also be provided for the start of actigraph use. 
 
Study staff will reset and recharge the actigra ph received from the LAR/caregiver, and that 
reset and recharged actigraph w ill be issued for use by [CONTACT_182990]/caregiver. 
 
6.1.3 Phone Visits to Assess Safety 
Safety information will be colle cted during phone calls at the end of Weeks 1, 4, 8, and 10 
(on Days 8, 29, 57, and 71, respectively). Th e LAR/caregivers will be queried about AEs, 
concomitant medications, and subj ect suicidality (Section 6.8). 
 
6.1.[ADDRESS_216127]’s LAR/caregiver will bring the study medication to the clinic and the 
morning dose will be administered at the clinic. The subject’s LAR/caregiver will bring the 
subject’s completed sleep diary and actigraph, and study staff will manage the sleep diary 
and actigraph during the visit as detailed in Section [IP_ADDRESS]. 
 
The following schedule of activities should be observed for subjects at the Week 2 clinic 
visits: 
 
1. Subject should have fasted overnight before coming to the clinic. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 61  
 
laborator y tests (Section 6.9 ) are performed. 2. Morning dose is administered in the clinic (s tudy staff will record time and date). On 
all clinic visit days, the morning dose must be administered before noon. 
 
3.  
 
 
4. Subject should eat a light low-fat breakfast (eg, cereal with low-fat milk, bagel with 
low-fat cream cheese, low-fat yogurt). 
 
5.  
 
Subject vital sign measurements and urine samp ling can be completed at any time during the 
visit. The LAR/caregiver questionnaires and investigator/study staff queries of the 
LAR/caregiver concerning AE s, concomitant medications, and subject suicidality 
(Section 6.8) can also be completed at any time during the visit. Any unacceptable 
tolerability of study drug asse ssed at this visit (eg, somnol ence, dizziness, vomiting, or 
change in behavior) must be reported as an AE. 
 
The subject and his LAR/caregiver will be expected to complete the dosing for the day of the 
Week 2 clinic visit (afternoon and evening doses) and continue study drug administration for the remainder of the treatment period. 
 
Details of the order of activities and instructions for assessments at the Week 2 clinic visit are provided in the workbooks for caregiver/clinician/subject assessments. 
 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph 
[IP_ADDRESS].[ADDRESS_216128], review, and issue a new sleep diary, as described for the baseline 
(Day 1) visit (Section [IP_ADDRESS].1). 
 
[IP_ADDRESS].2  Actigraph 
Study staff will upload data and issue a new acti graph, as described for the baseline (Day 1) 
visit (Section [IP_ADDRESS].2). 
At 3 to 4 hours postdose, P K blood sam pling is performed. 
At 0.5 to 0.75 hours postdose, P K blood sam pling and blood sam pling for clinical 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 62  
 
completed consent ) 
and ERP (if applicable consent provided ). 
laborator y tests (Section 6.9 ) are performed. 
6. 
At [ADDRESS_216129]’s LAR/caregiver will br ing the subject’s original study drug bottles 
(containing any unused study drug) to be collected by [CONTACT_5984]. The LAR/caregivers will also bring the subject’s completed sleep di ary and actigraph, and study staff will manage 
sleep diaries and actigraphs during the vi sit as detailed in Section [IP_ADDRESS]. 
 
Based on the returned study drug, study staff will assess complian ce and counsel the 
LAR/caregiver on proper administration of study drug, as needed. Study staff will enter the 
capsule counts for each bottle in the eCRF. Study staff will dispense (to the LAR/caregiver) 
the IWRS-assigned package of blinded study treatment for the subject’s second 6 weeks of 
treatment. 
 
The following schedule of activities should be observed for subjects at the Week 6 clinic 
visit: 
 
1. Subject should have fasted overnight before coming to the clinic. 
 
2. Morning dose is administered in the clinic (s tudy staff will record time and date). On 
all clinic visit days, the morning dose must be administered before noon. 
 
3.  
 
 
4. Subject should eat a light low-fat breakfast (eg, cereal with low-fat milk, bagel with 
low-fat cream cheese, low-fat yogurt).   
 
5. Study staff conduct the following assessments that involve subject participation, in 
the following order: KiTAP), RBANS, 
 
 
Subject vital sign measurements, urine sampling, 
can be completed at any time during the visit. The LAR/caregiver 
questionnaires and investigator/study staff qu eries of the LAR/care giver concerning AEs, 
At 0.5 to 0.75 hours postdose, P K blood sam pling and blood sam pling for clinical 
and cheek swab (if applicable based on 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216130] suicidalit y (Section 6.8) can also be completed at any 
time during the visit. Any unacceptable tolerability of study drug assessed at this visit (eg, 
somnolence, dizziness, vomiting, or change in behavior) must be reported as an AE. 
 
The subject and his LAR/caregiver will be expect ed to complete the dosing for the day of the 
Week 6 clinic visit (afternoon and evening doses) and continue study drug administration for the remainder of the treatment period. 
 
Details of the order of activities and instructions  for assessments at the Week 6 clinic visit are 
provided in the workbooks for caregiver/clinician/subject assessments. 
 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph 
[IP_ADDRESS].[ADDRESS_216131], review, and issue a ne w sleep diary, as described for the baseline 
(Day 1) visit (Section [IP_ADDRESS].1). 
 
[IP_ADDRESS].2  Actigraph 
Study staff will upload data and issue a new actigraph, as described for the baseline (Day 1) visit (Section [IP_ADDRESS].2). 
 
6.1.6 End-of-Treatment Visit 
The EOT visit is to be scheduled to occur at the end of Week 12. For subjects for whom study 
drug administration is stopped early (befor e Week 12), an EOT study visit should be 
conducted within [ADDRESS_216132]’s LAR/caregiver will bring the subject’s original study drug bottles 
(containing any unused study drug) to be collected by [CONTACT_5984]. Study staff will assess 
compliance with dosing instructions, entering the capsule count for each bottle in the eCRF. 
 
The LAR/caregiver will also brin g the subject’s sleep diary and actigraph, and study staff 
will manage the sleep diary and actigraph during the visit as detailed in Section [IP_ADDRESS]. 
 
The following schedule of activiti es should be observed for subjects at the EOT clinic visit: 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 64  
 
completed consent ) 
laborator y tests (Section 6.9 ) are performed. 
provided ). 1. Subject should have fasted overnigh t before coming to the clinic. 
 
2. Morning dose is a dministered in the clinic (study staff will record time and 
date). On all clinic visit days, the morn ing dose must be administered before 
noon. 
 
3.   
 
 
4. Subject should eat a light low-fat breakfas t (eg, cereal with low-fat milk, bagel 
with low-fat cream cheese, low-fat yogurt).   
 
5. Study staff conduct the following assessments that involve subject participation, 
in the following order: KiTAP,   RBANS, and ERP (if applicable consent 
 
6.  
 
Subject vital sign measurements, urine sampling, and cheek swab (if applicable based on 
can be completed at any time during the visit. The LAR/caregiver 
questionnaires and investigator/study staff qu eries of the LAR/caregiver concerning AEs, 
concomitant medications, and subject suicidalit y (Section 6.8) can also be completed at any 
time during the visit. Any unacceptable tolerabili ty of study drug assessed at this visit (eg, 
somnolence, dizziness, vomiting, or change in behavior) must be reported as an AE. 
 
Details of the order of activities and instructions for assessments at the EOT visit are 
provided in the workbooks for caregiver/clinician/subject assessments. 
 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph 
[IP_ADDRESS].[ADDRESS_216133], review, and issue a new sleep diary, as described for the baseline 
(Day 1) visit (Section [IP_ADDRESS].1). 
 
[IP_ADDRESS].2  Actigraphs 
Study staff will upload data and issue a new acti graph, as described for the baseline (Day 1) 
visit (Section [IP_ADDRESS].2). 
At 3 to 4 hours postdose, P K blood sam pling is performed. 
At 0.5 to 0.75 hours postdose, P K blood sam pling and blood sam pling for clinical 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 65  
 
The purpose of the EOS visit is to evaluate fo r possible acute rebound phenomena (eg, slee p 6.1.7 End-of-Study Visit 
 
disruption and behavior problems) that occur following discontinuation of study drug. The 
EOS visit will be scheduled to be completed wi thin [ADDRESS_216134]’s LAR/caregiver will bring the subj ect’s sleep diary and actigraph (issued at the 
EOT clinic visit), and study sta ff will manage the sleep diary and actigraph during the visit as 
detailed in Section [IP_ADDRESS]. 
 
The following schedule of activ ities should be observed for subjec ts at the EOS clinic visit: 
 
 Study staff conduct the following assessments that involve subject participation, in the 
following order: KiTAP and RBANS. 
 
The LAR/caregiver questionnaires and investigat or/study staff queries of the LAR/caregiver 
concerning AEs, concomitant medications, a nd subject suicidality (Section 6.8) can be 
completed at any time during the visit. 
 
Details of the order of activities and instructions for assessments at the EOS clinic visit are 
provided in the workbooks for caregiver/clinician/subject assessments. 
 
[IP_ADDRESS]  Management of Sleep Diary and Actigraph 
[IP_ADDRESS].[ADDRESS_216135] the sleep diary for recording in the eCRF. 
 
[IP_ADDRESS].[ADDRESS_216136]’s actigraph as described in the study manual. 
 
Actigraphs collected at the EOS clinic visit will be reset and recharged for re-issue and use 
by [CONTACT_182991]/caregiver. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 66  
 
(Riverside Publishin g, Rollin g Meadows, 6.2 Screening Assessments 
6.2.1 Autism Spectrum Disorder 
The investigator or qualified designee will revi ew the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5) criteria for autism spec trum disorder for each subject, specifically 
assessing social communication deficits and re stricted/repetitive behaviors and interests. 
 
6.2.[ADDRESS_216137] has an IQ less than 75. Standardized administration of the SB-5 begins by [CONTACT_17801] 2 routing subtests (1 from each of the verbal and nonverbal 
IQ domains) and using these routing subtest sc ores to determine the start points for the 
remaining verbal and nonverbal domains. Particip ants will be administered the complete SB- 
5 following standardized administration procedures 
IL). If a participant is not able to complete th e entire SB-5, the abbreviated battery IQ will be 
calculated from the 2 routing subtests. The abbr eviated battery IQ provides a quick estimate 
of 2 major cognitive factors: flui d reasoning and cr ystallized ability. 
 
A previous SB-5 documentation (within the 6 mont hs before the screening visit) can be used 
to qualify the subject as having an IQ less than 75. 
 
For the site in Israel, please see Appendix fo r site-specific details regarding the IQ test. 
 
6.3 Efficacy Assessments 
Efficacy assessments will be conducted according to the schedule presented in Table 6-1. The 
efficacy assessments, grouped by [CONTACT_182992] n and participant source, are presented in 
Table 6-2. Every effort should be made to ha ve the same LAR/caregiver complete the parent- 
reported questionnaires. Additionally, every effort should be made to have the same 
Investigator and raters complete the clinician assessments. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 67  
 Table 6-2 Efficacy Assessments by [CONTACT_182993]/Caregiver  Assessment Clinician  Assessment Direct Subject 
Assessment 
Behavior  ABC- C 
 ADAMS 
 RBS- R 
 Conners 3rd Edition 
 Short Sensory Profile-2   
Sleep  Children’s Sleep Habit Questionnaire 
 Sleep diary  Pediatric Sleep CGI scales and structured sleep history  Actigraphy 
Global functioning and quality of life  BASC-3 PRQ 
 PGI scales 
 Pediatric Quality of Life Inventory  Caregiver top 3 concerns visual analog scale 
 Vineland Adaptive Behavior Scale 
 CGI scales  
Cognitive measures    KiTAP 
 RBANS 
 ERP 
Abbreviations: ABC-C, Aberrant Behavior Checklist -Community; ADAMS, Anxiety, Depression, and Mood 
Scale; BASC-[ADDRESS_216138] Edition Parenting Relationship 
Questionnaire; CGI, clinical global impressions; ERP, event related potential; KiTAP, Test of Attentional Performance for Children; LAR, legally acceptable representative; PGI, parent global impressions; 
RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; RBS-R, Repetitive Behavior Scale-Revised.
  
 
 
6.3.1 Caregiver Assessments 
[IP_ADDRESS]  Aberrant Behavior Checklist-Community 
The Aberrant Behavior Checklist-Community (ABC-C) is a 58-item questionnaire completed 
by [CONTACT_55639]/caregiver that assesses a wide range of behaviors, including irritability, 
lethargy/social withdrawal, inappropriate spee ch, hyperactivity, stereotypic behavior, and 
social avoidance. Each item is rated on a scale of 0 to 3 (“not at all a problem” to “the 
problem is severe in degree”). The ABC-C will  be scored 2 ways: according to the original 
method used to assess a population with a variety of disabilities (Aman et al 1985) and 
according to a method adapted for FXS that has a 6-factor structure (Sansone et al 2012). In the 6-factor method, 1 factor is unchanged from the original scoring (inappropriate speech); 4 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 68  
 factors are modified (irritability, hyperactivity, lethargy/withdrawal, and stereotypy); and 1 
new factor (social/avoidance) has been added. 
 
[IP_ADDRESS]  Anxiety, Depression, and Mood Scales 
The Anxiety, Depression, and Mood Scales (ADAMS) is a caregiver-completed report that 
screens comprehensively for anxiety and depres sion in persons with intellectual disability 
and consists of 28 items grouped into 5 subscales that assess the frequency and severity of 
manic/hyperactive behavior, depressed mood, social avoidance, general anxiety, and 
obsessive behavior (E sbensen et al 2003). 
 
[IP_ADDRESS]  Repetitive Behavior Scale-Revised 
The Repetitive Behavior Sc ale-Revised (RBS-R) is a caregiver-completed, 43-item 
questionnaire assessing a variety of repetiti ve behaviors with 6 behavior subscales: 
stereotyped, ritualistic, self-injurious, compul sive, restricted, and sameness (Bodfish et al 
2000). 
 
[IP_ADDRESS]  Conners 3rd Edition 
The Conners 3rd Edition (Conners 3; North Tonawanda Multi-Health System, North 
Tonawanda, NY) is designed to assess attention deficit hyperactivity disorder, and it will be 
used to collect LAR/caregiver observations of subject behavior. The assessment of behavior 
in neurodevelopmental disorders, such as FXS, frequently relies upon proxy report. The long form of Conners 3 is needed to assess inc onsistency (reporter reliability) and will be 
administered at Screening only. The short form  of Conners 3 will be administered as an 
outcome assessment at the baseline, Week 2, Week 6, EOT, and EOS visits. 
 
[IP_ADDRESS]  Short Sensory Profile-[ADDRESS_216139]’s sensory 
processing patterns in the context of hom e, school, and community-based activities 
(PsychCorp, San Antonio, TX).  
 
[IP_ADDRESS]  Children’s Sleep Habits Questionnaire 
The Children’s Sleep Habits Questionnaire (C SHQ) is a caregiver-completed assessment of 
sleep behaviors in children and adolescents (Owe ns et al 2000). The abbreviated version of 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 69  
 this questionnaire includes 33 items that asse sses sleep habits and possible difficulties with 
sleep. The CSHQ should take 5 to 10 minutes to complete. 
 
[IP_ADDRESS]  Sleep Diary 
A paper sleep diary will be completed by [CONTACT_6992]’s LAR/caregiver, on behalf of the 
subject. Endpoints assessed by [CONTACT_182994] e presented in Section 7.3.1. The sleep diary 
will be completed each day during the 7 days immediately preceding each clinic visit after 
screening. The LAR/caregiver will continue to  complete a sleep diary for a subject who is 
unable to tolerate wearing an  actigraph (Section [IP_ADDRESS]). 
 
At each clinic visit when a sleep diary is issu ed (Table 6-1), a calendar will be issued to 
remind the LAR/caregiver when next to start reco rding data in the sleep diary. Sleep diaries 
will be collected at each clinic visit, starting with the baseline visit (Table 6-1). 
 
[IP_ADDRESS]  Behavior Assessment System for Children, 3rd Edition 
The Behavior Assessment System for Children, 3rd Edition, Parenting Relationship 
Questionnaire (BASC-3 PRQ) provides informat ion on the relationship between a caregiver 
and a child across multiple dimensions (Pearson, [LOCATION_001], NY). It yields the following 
subscale scores: attachment, communication,  discipline practices, involvement, parent 
confidence, satisfaction with school, and relati on frustration. The questio nnaire is written at a 
third grade level and also calculates a nu mber of response validity scores, such as 
consistency and response pattern, to detect ca reless or exaggerated responding. It includes 
normative samples for both female and male raters that are closely matched to the US Census population estimates. 
 
[IP_ADDRESS]  Parent Global Impressions Scales 
The Parent Global Impression s-Severity (PGI-S) scale will be completed by [CONTACT_182995]/caregiver to assess the severity of symptoms, and the Parent Global 
Impressions-Improvement (PGI-I) scale will be used by [CONTACT_55639]/caregiver to assess 
improvement from baseline. The PGI-S has been adapted to capture specific characteristics 
commonly present in the FXS population. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 70  
 [IP_ADDRESS]  Pediatric Quality of Life Inventory 
The Pediatric Quality of Life Inventory (PedsQ L) generic core scales and Multidimensional 
Fatigue Scale will be administered in this study (Varni et al 2004). The generic core scales 
include 23 items covering the domains of physical, emotional, social, and school functioning. 
The Multidimensional Fatigue Scale contains 18 items measuring general fatigue, sleep/rest 
fatigue, and cognitive fatigue. 
 
6.3.2 Clinician Assessments 
[IP_ADDRESS]  Structured Sleep History Form 
On the initial screening visit, the clinician will  complete parts A, B, and C of the structured 
sleep history form by [CONTACT_182996]/caregi ver. The sleep history form is used by [CONTACT_182997] a source document for completi on of the Pediatric Sleep Clinical Global 
Impressions (Pediatric Sleep CGI) scales (Section [IP_ADDRESS]). On all subsequent clinic visits starting with baseline, the clinician will complete only part A of the structured sleep history 
form. Part D of the structured sleep history form will not be used for this study. 
 
[IP_ADDRESS]  Pediatric Sleep Clinical Global Impressions Scales 
The Pediatric Sleep CGI scales were recently developed to measure pediatric insomnia in 
autism spectrum disorder and have been validated against the CSHQ and actigraphy (Malow 
et al 2016). The clinician will interview the LAR/caregiver for each subject to complete the 
structured sleep history form (Section [IP_ADDRESS]) as an aid to the clinician completing the 
Pediatric Sleep CGI-Severity and Pediatric Sleep CGI-Improve ment scales as scheduled 
(Table 6-1). Questions include the subject's ab ility to fall asleep and remain sleepi[INVESTIGATOR_182962] (ie, apart from LAR/caregivers);  bedtime resistance; sleep onset delay; night 
awakening; LAR/caregiver satisfaction with th eir child's current sleep patterns; family 
functioning, as affected by [CONTACT_150359]'s current sleep patterns; and clinician's overall concern 
with the child's sleep. 
 
[IP_ADDRESS]  Caregiver Top 3 Concerns Visual Analog Scale 
In Part 1 of the visual analog scale (VAS), LA Rs/caregivers will generate their top [ADDRESS_216140]. The investigator will then map each LAR/caregiver-generated concern onto 
one FXS-specific domain (e.g. communication, ac tivities of daily living, anxiety) to which 
each behavior or symptom applies. Part 2 of VAS will be used to rate FXS-specific domains, 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 71  
 including speech and communication, socialization, and cognition. The investigator will ask the 
LAR/caregiver to rate the behaviors in both Part 1 and 2, using a 10-cm VAS, with the 
descriptive anchors of “worst ever” and “best ever.” . 
 
[IP_ADDRESS]  Vineland Adaptive Behavior Scale 
The Vineland Adaptive Behavior Scale, 3rd Edition (VABS-3) caregiver interview form will 
be used to evaluate communication, socializatio n, and daily living skills of subjects to assess 
their overall adaptive functioning (PsychCorp, San Antonio, TX). This assessment is an 
interview of the caregiver by a trained qualified rater. 
 
[IP_ADDRESS]  Clinical Global Impressions Scales 
The CGI-S scale will be used by [CONTACT_182998], and the 
CGI-I scale will be used by [CONTACT_182999]. The CGI-S 
has been adapted to capture specific characteristics commonly present in the FXS population. 
Both CGI-S and CGI-I will be conducted by a clinician with experience in FXS. 
 
6.3.[ADDRESS_216141] Assessments 
[IP_ADDRESS]  Actigraphy 
Actigraphy is a noninvasive method of monito ring human rest/activity cycles. A small 
actigraph unit is worn to measure daytime and sleep activity. The actigraph unit stores motion 
data by [CONTACT_183000], and the data must be uploaded to an actigraphy database for analysis. 
 
Each subject will be provided a wearable acti graph unit (Actiwatch; Philips Respi[INVESTIGATOR_130747], 
Murrysville, PA), preferably to be worn on the nondominant wrist. If the subject is not able to 
tolerate the Actiwatch on his wrist, he may wear it on his ankle. The Actiwatch can be 
attached with a hospi[INVESTIGATOR_182963]. Once a body 
location is selected for attachment of the Actiwatch, every effort should be made to keep the 
location the same throughout the study. Severe  sensory sensitivities exist in the study 
population, and it is anticipated that some subj ects will not be able to tolerate wearing the 
device. Therefore, if a subject is not able to tolerate the Actiwatch and/or comply with the 
Actiwatch guidelines, he may continue to part icipate in the study. The Actiwatch will be 
worn during the 7 days immediately preceding eac h clinic visit after screening. It should be 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 72  
 worn continuously throughout the day and nigh t for 7 consecutive days. The actigraphy data 
(Section 7.3.3) will be compared to the sleep diary data. 
 
[IP_ADDRESS]  Test of Attentional Performance for Children 
The KiTAP is an automated computer-based assessment of attentional performance 
developed and normed for a pediatric population. The KiTAP is suitable for assessment of function in individuals of various ages, including  children, adolescents, and adults, with FXS 
(Knox et al 2012). The task displays an “encha nted castle” animation and measures 8 aspects 
of attention: alertness, distractibility, divi ded attention, flexibility, go/no-go, sustained 
attention, vigilance, and visual scanning. 
 
[IP_ADDRESS]  Repeatable Battery for the Assessment of Neuropsychological 
Status 
The RBANS provides a brief individually administer ed battery to assess cognitive function in 
individuals 12 years of age and older (Randolph et al 1998). The full battery consists of 
12 subtests to assess immediate memory, visuos patial abilities, language, attention, and 
delayed memory. In this study, 6 subtests of the RBANS will be used: list learning 
(immediate memory), list recall (delayed memo ry), list recognition (delayed memory index), 
story memory (immediate memory index), stor y recall (delayed memory index), and pi[INVESTIGATOR_182964] (language index). Each subtest can be administered in 5 minutes or less. 
 
[IP_ADDRESS]   
 
Electroencep halogram (EEG)  recor dings w ill be use d to character ize rest ing EEG  and ERP,  
and to assess treatment response an d assoc iated changes in cort ical activity (Ethridge et a l  
2016) . Subjects w ill pass ively listen to 150 pairs (S1, S2) of 5-msec broadband noise bursts  
(65 dB) separate d by [CONTACT_183001]-stimulus interva l of 500 msec. Inter-trial interva ls will be 4000  
msec (average ), for a tota l task duration of 11.25 minutes. Data from an  
electroencep halogram w ill be acqu ired cont inuous ly at a 1000  Hz samp ling rate, an d will be 
filtered online at 0.1 to 100 Hz, amp lified (12,500×), and digitized (1000  Hz). Part icipants  
will view a stan dard silent mov ie of their choice during electroencep halogram recor ding. If  
the part icipant in una ble to cooperate for the ERP testing, he will not be withdrawn from t he 
study. Sites w ill be strong ly recommen ded to con duct EEG/ERP  assessments (if applicable  
based on EEG/ERP  feasibility an d comp leted consent ).  Event Related Potential 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216142] partici pation in ex plorator y laborator y assessments is based on com pletion of 
separate, o ptional informed consents. 
6.4.1 Metabolomic Biomarkers 
A minimum of 4 mL of blood will be drawn (1 green-to p sodium he parin tube ) for the 
purpose of identif ying metabolomic biomarkers in plasma whose levels are associated with 
plasma levels of OV101, clinical presentation of FXS, o r treatment res ponse. Se parated 
plasma will be sub jected to li quid chromato graphy/high resolution mass s pectrometr y for 
metabolomic anal yses, which will be com pared to those from sam ples ac quired from a 
biorepositor y from a ge-matched t ypi[INVESTIGATOR_182965] y metabolomic 
biomarkers whose levels are associated with FXS. 
6.4.[ADDRESS_216143] 
microbiomes will be performed with the goal of identif ying microbiome s pecies whose levels 
are associated with FXS clinical presentation or treatment res ponse to OV101. Sam ples 
acquired from a biorepositor y from a ge-matched t ypi[INVESTIGATOR_182966] y species whose levels are associated with FXS. 
Data generation and anal ysis will be conducted by [CONTACT_183002] ([LOCATION_001], NY ), and the 
results ma y be reported se paratel y. 
6.5 Plasma OV101 Concentrations 
Blood for determinin g plasma OV101 concentrations will be drawn a t each s pecified clinic 
visit (Table 6-1 ) 0.5 to 0.75 hours and 3 to 4 hours after administration of the mornin g dose 
in the clinic. 
Plasma OV101 concentration data obtained in this stud y may be combined with data fro m 
prior studies to perform population P K and P K-PD anal yses and to evaluate the  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Exploratory Laboratory Assessments 6.4 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 74  
 
reported se paratel y from the clinical stud y report (CSR ) for this stud y.  
 
 
 
 
6.6 Safety and Tolerability Assessments 
All subjects who receive study drug will be evaluated for study drug safety and tolerability. 
Assessments will include the frequency and severity of treatment-emergent AEs (TEAEs) 
and SAEs (including TEAEs leading to discontinuation), standardized clinical assessment of 
suicidality, clinical laboratory evaluation s, and vital sign measurements. Safety and 
tolerability assessments will be conducted accor ding to the schedule presented in Table 6-1. 
 
6.6.1 Adverse Events 
[IP_ADDRESS]  Definitions of Adverse Events 
The investigator is responsible for reporting all AEs that are observed or reported during the study, regardless of their relationship to st udy drug or their clinical significance. 
 
An AE is defined as any untoward medical occu rrence in a subject enrolled into this study 
regardless of its causal relationship to study drug. Subjects will be instructed to contact [CONTACT_183003]. 
 
A TEAE is defined as any event not present before exposure to study drug or any event 
already present that worsens in either intensity or frequency after exposure to study drug. 
 
[IP_ADDRESS]  Serious Adverse Events 
An SAE is defined as any event that meets one of the following criteria: 
 
 Results in death 
 Is immediately life threatening 
 Requires inpatient hospi[INVESTIGATOR_1081] 
 Results in persistent or significant disab ility/incapacity not consistent with baseline 
level 
 Is a congenital anomaly/birth defect 
exposure-res ponse of OV101 in individuals with FXS. The results of these anal yses will be 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216144] or may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition.  Examples of such medical events include 
allergic bronchospasm requiring intensive treatm ent in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of 
drug dependency or drug abuse. 
 
[IP_ADDRESS]  Eliciting and Documenting Adverse Events 
Adverse events will be assessed beginning at enrollment (date of signed informed consent) 
and up to [ADDRESS_216145]’s last study drug dose, whichever comes first. 
 
Serious AEs that occur more than [ADDRESS_216146] dose of study drug need not be 
reported unless the investigator cons iders them related to study drug. 
 
At every clinic visit after informed consent and at all phone visits (Table 6-1), subjects will 
be asked a standard nonleading question to elic it any medically related changes in their 
well-being. They will also be asked if they ha ve been hospi[INVESTIGATOR_057], had any accidents, used 
any new medications, or changed concomitant medication regimens (both prescription and 
over-the-counter medications). 
 
In addition to subject observations , AEs identified from any study data (eg, laboratory values, 
physical examination findings) or identified from the review of other documents (eg, subject 
diaries) that are relevant to subject safety or considered to be clinically significant, in the 
medical and scientific judgment of  the investigator, will be documented on the AE page in 
the eCRF. 
 
[IP_ADDRESS]  Reporting Adverse Events 
All AEs reported or observed during the study will be recorded on the AE page in the eCRF. Information to be collected  includes the following: 
 
 Drug treatment 
 Dose 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 76  
 
Ovid/Sciformix 
Ovid/Sciformix 
Ovid/Sciformix 
number )  Event term (diagnosis, not symptoms) 
 Time of onset 
 Investigator-specified assessment of se verity and relationship to study drug 
 Time of resolution of the event 
 Seriousness 
 Any required treatment or evaluations 
 Outcome 
Adverse events resulting from concurrent illn esses, reactions to concurrent illnesses, 
reactions to concurrent medications, or progress ion of disease states must also be reported. 
All AEs will be followed to adequate reso lution. The Medical Dictionary for Regulatory 
Activities (MedDRA) will be used to code all AEs. 
 
Any medical condition that is present at the ti me that the subject is screened but does not 
deteriorate should not be reported as an AE. Howeve r, if it deteriorates at any time during the 
study, it should be recorded as an AE. 
 
[IP_ADDRESS]  Reporting Serious Adverse Events 
Investigators and other study center staff must immediately (ie, within 1 business day) inform 
upon learning of any SAE that occurs (whether or not attributable to the 
study drug). It is the investigator’s responsibility to ensure that SAE reporting procedures are 
followed appropriately. All SAE reports must be faxed to the following number. 
 



Any AE that meets SAE criteria (Section 6.6. 1.2) must be entered into the EDC system 
immediately (ie, within 1 business day) after site personnel first learn about the event. Once 
the qualifying SAE data are entered, will be notified by [CONTACT_183004], which 
will contain high-level safety information. Additional safety information will be obtained 
from the EDC system via applicable eCRF pages. If the EDC system is not available, the site 
should send a completed, manual, paper SAE report form to by [CONTACT_6791]: 
Safet y Hotline: [PHONE_3924] (note: this is a combined phone and fax toll-free 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 77  
 
Inc. 2017 ).

When the EDC system is again available, the s ite must enter all applicable information into 
the EDC system. All supporting source info rmation concerning the SAE (eg, hospi[INVESTIGATOR_2553]) should be provided by [CONTACT_6791].   
 
If there is a question concerning an SAE, the site needs guidance regarding the reporting of 
an SAE, the site is returning a call from a Sciformix safety specialist, or the site urgently needs to report an SAE or make 
used: 
 
aware of an SAE, the safety hotline should be 
 
If a site makes an initial report of an SAE by [CONTACT_19647], the site must subsequently 
enter all applicable information into the EDC system immediately thereafter. 
 
All SAEs must be reported starting from the time that informed consent for study 
participation is provided. If the investigator becomes aware of an SAE within [ADDRESS_216147]’s last dose of study drug or within [ADDRESS_216148] be followed un til the event resolves, the event or sequelae 
stabilize, or it is unlikely that additional in formation can be obtained  after demonstration of 
due diligence with follow-up efforts (ie, the subj ect or health care practitioner is unable to 
provide additional information or the subject is lost to follow-up). Serious AEs that occur more than [ADDRESS_216149] dose of study drug do not need to be reported unless the 
investigator considers them related to study drug. 
 
[IP_ADDRESS]  Suspected Unexpected Serious Adverse Reactions 
The sponsor will promptly evaluate all su spected unexpected seri ous adverse reactions 
(S[LOCATION_003]Rs) and nonserious AEs of special interest  against cumulative product experience to 
identify and expeditiously communi cate possible new safety find ings to investigators, IRBs, 
and applicable health authorities, based on applicable legislation. 
 
To determine the reporting requirements for single AE cases, the sponsor will assess the expectedness of these events using the gaboxadol  investigator’s brochure (Ovid Therapeutics 
Safet y Hotline: [PHONE_3924] 
Sciformix 
Safet y Fax Line: [PHONE_3924] 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 78  
 The sponsor will compare the severity of each  suspected unexpected serious adverse reaction 
and the cumulative event frequency reported for the study with the severity and frequency 
reported in the investigator’s brochure. 
 
Reporting requirements will also be based on the investigator's assessment of causality and 
seriousness, with allowance for upgrading by [CONTACT_183005]. 
 
[IP_ADDRESS]  Assessment of Severity 
The severity, or intensity, of an  AE refers to the extent to wh ich an AE affects the subject’s 
daily activities. The intensity of the AE will be  rated as mild, moderate, or severe using the 
following criteria: 
 
Mild: An AE that is transient in nature a nd generally does not interfere with the 
subject’s normal activities. 
Moderate: An AE that is sufficiently discomfortin g to interfere with the subject’s normal 
activities. 
Severe: An AE that is incapacitating and prevents normal activities. 
 
 
Changes in the severity of an AE should be documented to allow an assessment of the 
duration of the event at each level of intensity to be performed. Adverse events characterized 
as intermittent do not require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. 
 
[IP_ADDRESS]  Assessment of Causality 
The investigator’s assessment of an AE’s relationship to study drug is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the 
study. If there is any doubt as to whether a clinical observation is an AE, the event should be 
reported. 
 
The relationship or association of  the test article in causing or contributing to the AE will be 
characterized using the following classification and criteria: 
 
Unrelated: This relationship suggests tha t there is no association between the study drug 
and the reported event. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 79  
  
Possible: This relationship suggests that treatment with the study drug caused or 
contributed to the AE, ie, the event follows a reasonable temporal sequence 
from the time of drug administration or follows a known response pattern to the study drug but could also have be en produced by [CONTACT_1604]. 
Probable: 
This relationship suggests that a reasonable temporal sequence of the event 
with drug administration exists and, based upon the known pharmacological 
action of the drug, known or previously  reported adverse reactions to the drug 
or class of drugs, or judgment based on the investigator’s clinical experience, 
the association of the event with the study drug seems likely. The event 
disappears or decreases on cessation or re duction of the dose of study drug. 
Definite: This relationship suggests that a defini te causal relationship exists between drug 
administration and the AE, and other conditions (concurrent illness, 
progression/expression of disease state,  or concurrent medication reaction) do 
not appear to explain the event. The ev ent reappears or worsens if the study 
drug is re-administered. 
 
 
[IP_ADDRESS]  Follow-up of Subjects Reporting Adverse Events 
All AEs must be reported in detail on the a ppropriate page in the eCRF and followed to 
satisfactory resolution, until the investigator deems the event to be chronic or not clinically 
significant or until the subject is considered to be stable. 
 
6.6.2 Other Safety Assessments 
Safety assessments other than AEs (Section 6.6.1) will include standardized clinical assessment of suicidality (Section 6.8), clinical  laboratory evaluations (Section 6.9), and vital 
sign measurements. 
 
[IP_ADDRESS]  Vital Sign Measurements 
Vital sign measurements will include weight, blood pressure, heart rate, and temperature. 
Measurements of blood pressure, heart rate, a nd temperature should be attempted after the 
subject has been resting in a supi[INVESTIGATOR_182967] [ADDRESS_216150], and 
time of meetings. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216151]’s 
LAR/caregiver the following questions (and record the answers in the eCRF): 
 
1. Suicidal ideation: Has the subject wished he were dead or wished he could go to sleep 
and not wake up? 
 
2. Suicidal behavior: Has the subject made a suicide attempt? Has the subject done 
anything to harm himself? 
 
3. Self-injurious behavior: Has the subject engaged in nonsuicidal self-injurious 
behavior? 
 
If the investigator determines that any of these questions can be asked directly to the subject 
based on his ability to understand and respond to  the questions, then those questions should 
be directed to the subject. If the answer to any of these 3 questions is “yes,” then the investigator will further evaluate the suicidal risk of the subject. 
 
6.[ADDRESS_216152] results (hematology, clinical chemistry, or urinalysis), including 
those that worsen from baseline, that are consider ed to be clinically significant in the medical 
and scientific judgment of th e investigator are to be recorded as AEs or SAEs. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 81  
 
OV101 (PK assessment ): Blood sam ples will be collected fo r determination of plasma 
concentrations of OV101. 
Details concernin g the collection, processin g, and handlin g of cheek swabs for microbiome 
assessments can be found in the [COMPANY_003] Central Laborator y manual. The following clinical analytes will be assessed: 
 
Hematology (safety assessment): hematocrit; hemoglobin; red blood cell count with indices 
(mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular 
hemoglobin concentration); reticulocytes;  white blood cell count and differential 
(neutrophils, lymphocytes, monocytes, eosinophi ls, and basophils) re ported as percentages 
and absolute values; and platelets (platelet count, prothrombin time and partial 
thromboplastin time, interna tional normalization ratio). 
 
Clinical chemistry (safety assessment): albumin; alkaline phosphatase; blood urea nitrogen; 
gamma-glutamyl transferase; calcium; crea tinine; glucose; cholesterol (high-density 
lipoprotein and low-density lipoprotein [c alculated] and homogenous low-density 
lipoprotein); triglycerides; phosphate; potassium; alanine aminotransferase; aspartate 
aminotransferase; lactate dehydrogenase; sodium ; chloride; bilirubin (total, direct); total 
protein; uric acid; and creatine phosphokinase. 
 
Urinalysis (safety assessment): macroscopic (pH, specific gravity, glucose, protein, ketones, 
nitrates, blood) and microscopic, reported only  if present (red blood cells/high-power field, 
white blood cells/high-power field, casts, epi[INVESTIGATOR_1663], crystals, granulation). 
 
 
 
6.10 Sample Collections 
Blood and urine samples collected from subjects will be forwarded to a central laboratory for analysis. Further details regarding sample collections and processing and specific testing can 
be found in the study manual (provided to study sites as a separate document). 
 
All samples for clinical laboratory analysis will  be collected as described in Section 6.1 and 
the investigator’s study manual, according to th e schedule of activities  (Table 6-1). Samples 
for hematology, clinical chemistry, or urinalysis will be used only for the evaluation of safety 
and tolerability. 
 
 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 82  
 
OV101 plasma concentrations, and (optionall y) determination of metabolomic biomarkers. Blood samples will be collected for clinical laboratory safety assessments, 
 
The maximum volume of blood to be collected per subject over the course of the study is 
estimated to be less than 140 mL. 
determination of 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 83  
 7 Statistical and Analytical Plan 
7.1 Primary Safety Endpoints 
Treatment-emergent AEs, treatment-related TEA Es, TEAEs leading to study discontinuation, 
and SAEs will be evaluated as primary safety endpoints. 
 
7.2 Secondary Efficacy Endpoints 
The efficacy parameters of the continuous secondary endpoints will be the mean changes 
from baseline in ABC-C total and subscale scor es; in ABC-C factor score for FXS; in the 
ADAMS subscale scores; in the RBS-R total and subscale scores; in Conners 3 subscale 
scores; in the Short Sensory Profile-2 total an d subscale scores; and in the CGI-S and CGI-I 
scores. 
 
7.3 Exploratory Efficacy Endpoints 
The exploratory efficacy e ndpoints below are not listed in order of importance. 
 
7.3.1 Caregiver-Completed Endpoints 
 Change from baseline in the BASC-3 PRQ subscale scores 
 
 Change from baseline in PGI-S and PGI-I scores 
 
 Change from baseline in PedsQL  total and subscale scores 
 
 Change from baseline in the CH SQ total and subscale scores 
 
 Change from baseline in sleep diary pa rameters, including how long it took the 
subject to fall asleep (sleep onset latency [SOL]), the amount of time the subject was 
awake during the night (WASO), the total amount of sleep obtained (total sleep time 
[TST]), and daytime sleepi[INVESTIGATOR_008], defined as  duration of nappi[INVESTIGATOR_182968]. 
 
7.3.2 Clinician-Completed Endpoints 
 Change from baseline in top 3 concerns visual analog scale 
 
 Change from baseline in the VABS-3 overall composite and subscale scores 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 84  
 7.4 Other Exploratory Endpoints 

Mean chan ge from baseline in ERP res ponse 

Levels of plasma OV101 concentrations at sam pling time points 

Chan ges from baseline in sub ject microbiomes 

Chan ges from baseline in biomarkers  Change from baseline in Pediatric Sleep CGI-Severity and Pediatric Sleep 
CGI-Improvement scores 
 
7.3.[ADDRESS_216153] Assessment Endpoints 
 Actigraphy parameters for sleep, incl uding SOL, WASO, sleep fragmentation, 
number of nocturnal awakenings, TST, sleep efficiency, and daily activity level. 
 
 Mean change from baseline in KiTAP subtest scores 
  
 Mean change from baseline in RBANS subtest scores 
 
 
 
  
 
7.5 Sample Size Calculations 
A sufficient number of subjects (36 estimated) will be enrolled to ensure that 30 evaluable 
subjects complete 12 weeks of treatment. Subjects will be randomly assigned to the 3 OV101 
total daily dosing regimens in a 1:1:[ADDRESS_216154] ratified by [CONTACT_551] (adolescents/adults), with 
a target ratio of 1:1 between adolescents and adults. 
 
The main emphasis in reporting the data will be on descriptive statistics and estimation with 
95% CIs. 
 
For the objective of estimating the overall su bject incidence of TEAEs (for the 3 OV101 total 
daily dose arms combined), the precision varies with true inci dence, eg, a true incidence of 
20% would be estimated with a 13.9% precision (half-width of the 2-sided 95% CI, assuming N = 30). Table 7-1 contains the estimated precision for different incidence rates, using the 
Wilson method of calculating a confidence interval for a binomial proportion. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 85  
 Table 7-1 Incidence Rates and Corresponding Precision 
 
True TEAE Incidence Rate 10% 13.3% 20% 23.3% 30% 
Expected n with a TEAE 
(N=30) 3 4 6 7 9 
Expected proportion, p 0.100 0.133 0.200 0.233 0.300 
95% CI (3.5%, 25.6%) (5.3%, 29.7%) (9.5%, 37.3%) (11.8%, 40.9%) (16.7%, 47.9%) 
Precision (half-width of CI) 11.1% 12.2% 13.9% 14.6% 15.6% 
Note: All CIs are 2-sided and 95% CIs are calculated using Wilson’s method. 
Abbreviations: n, number of subjects observed; N, total number of evaluable subjects in the study (all treatment 
groups); TEAE, treatment-emergent adverse event. 
 
 
7.6 Analysis Sets 
The following analysis sets are defined: 
 
Randomized Analysis Set: The randomized analysis set will consist of  all randomly assigned 
subjects. 
 
Full-Analysis Set (FAS): The FAS will consis t of all randomly assigned subjects who receive 
at least [ADDRESS_216155] 1 postbaseline efficacy assessment. Following 
the intent-to-treat principle, subjects will be  analyzed according to the treatment they are 
assigned to at randomization, regardless of compliance or any deviations from the study 
protocol. 
 
Modified Full-Analysis Set (mFAS): The mFAS wi ll consist of all subjects in FAS, excluding 
data after a subject discontinues treatment or commences treatmen t with a prohibited 
medication. 
 
Safety Set: The safety set will consist of all subjects who receive at least [ADDRESS_216156] disposition, 
demographics, and other baseline characteristics. All safety evaluations will be carried out on 
the safety set. All efficacy evaluations will be carried out on the FAS. The mFAS may be used for exploratory modelling of selected ef ficacy variables, in addition to the FAS. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 86  
 7.7 Description of Subgroups to be Analyzed 
Scatter plots of data will distinguish the age gr oups (adolescent/adult) with different symbols 
to allow visual assessment of the consistency of data between these groupi[INVESTIGATOR_14839]. In addition, 
listings of all data will identify the age group of  each subject. In the case of an endpoint that 
is further analyzed through the Mixed Model with Repeated Measures (MMRM; Section 7.8.5) and for which differences between age groups are apparent, an age by [CONTACT_183006] (in addition to overall). 
 
Additional subgroup statistical analyses may be performed, as detailed in a separate 
statistical analysis plan. 
 
7.8 Statistical Analysis Methodology 
The detailed methodology for the summary and statistical analyses of the data collected in 
this study will be doc umented in a separate statistical analysis plan. This document may 
modify the plans outlined in the protocol; howev er, any major modifications of the endpoint 
definitions and/or their analyses will also  be reflected in a protocol amendment. 
 
All statistical analyses will be performed using SAS software Version 9.3 or higher. 
 
Descriptive statistics (number of subjects, me an, SD, median, minimum, and maximum) will 
be presented for continuous variables and their changes from baseline. In addition, 95% CIs 
for the mean change from baseline will be provided for continuous variables. Graphical 
displays will be utilized to in vestigate trends over time and dose and the relationship between 
certain variables and differences between age groups. 
 
Ordinal variables with sufficient numerical cat egories (eg, 7-point scales of PGI-S and 
CGI-S) and subscale total scores from questionna ires will be treated as continuous variables. 
 
Categorical (not treated as continuous) endp oints (including AE incidence and binary 
endpoints) will be summarized by [CONTACT_7237]. Frequencies and percentages 
will be presented for the shifts in these categories (eg, low to normal, low to high, high to 
low) from baseline to each po st-treatment assessment time poin t for scales with categorical 
variables. If there are missing values, the number missing will be presented (as a category), but without a percentage. All data collected will be included in by-s ubject data listings. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 87  
 7.8.1 Safety Analyses 
All safety analysis will be performed on the safety set. 
 
All AEs will be coded using MedDRA and will be classified by [CONTACT_11189] 
(SOC) and preferred term (PT). 
 
The number and percentage of subjects who experience at least [ADDRESS_216157] 1 TEAE within each specific SOC and PT will 
be presented by [CONTACT_183007]. The number of TEAE s (event incidence) 
will also be summarized within each SOC and PT. 
 
The Wilson 95% CIs will be displayed for the prop ortion of subjects experiencing TEAEs as 
a total across the [ADDRESS_216158] based on the investigat or’s assessment. The number and percentage 
of subjects reporting SAEs, TEAEs, and AEs leading to study continuation will also be summarized by [CONTACT_55366]. 
 
For each SOC and each PT, a subject will be counted only once for subject-incidence 
tabulations. For summaries of severe or tr eatment-related AEs, for a given subject, the 
highest severity or relationship for a specific PT will be considered. Adverse events with 
missing start dates will be considered treatment emergent. 
 
Number and percentage of  deaths will be tabulat ed by [CONTACT_183008]. 
 
Descriptive statistics for labora tory values and vital sign measurements at each time point 
will be summarized. Clinically signific ant laboratory values may be tabulated. 
 
Shift tables for laboratory parame ters will be presented to show the change of normality from 
baseline to each postbaseline visit. For each co ntinuous laboratory parameter, results will be 
categorized as low, normal, or high based on the laboratory reference ranges . Frequencies 
and percentages will be presented for the shifts in these categories (eg, low to normal, low to 
high, high to low) from baseline to each post-treatment assessment time point. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 88  
 7.8.4 Analyses of Other Exploratory Endpoints 
Key outcomes for ERP will be chan ges in am plitude and latenc y of N1 and P2 waveforms as 
well as chan ges in percen t habituation of N1 am plitude. Anal yses across the entire waveform 
will be more ex plorator y, examinin g any unantici pated effects of treatment. Tables and graphical displays (eg, scatter plot s of baseline versus worst postbaseline values) 
of key safety parameters may be generated to bette r understand the study drug safety profile. 
 
Shift tables for Clinical Assessment of Suicida lity data will be presented to show the change 
in answers (yes/no) from baseline to postbaseline visits. 
 
Abnormal findings in physical examinations will be listed. 
 
Concomitant medications will be coded using the World Health Organization Drug 
Dictionary. A table summarizing concomitant medications and a by-subject listing of 
concomitant medications will include all medications taken during the study regardless of the 
timing for the start of the medication. 
 
7.8.[ADDRESS_216159]-hoc explorat ory modelling may be conducted on selected 
variables (Section 7.8.5) using th e FAS (and mFAS, as required). 
 
7.8.[ADDRESS_216160]-hoc exploratory modelling may be conducted on selected variables 
(Section 7.8.5) using the FA S (and mFAS as required).   
 
 
 
 
 
 Individual plasma OV101  concentrat ions w ill be listed, plotted, and summar ized in the same 
way as ot her cont inuous en dpoints (number of subjects, mean, SD, median, m inimum, an d  
maximum ). The plasma OV101  concentrat ions w ill be use d in com bination w ith data from 
other stu dies to inform popu lation PK an d PK-PD ana lyses an d to eva luate t he exposure-  
response o f OV101  in individuals with FXS.  

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 89  
 
generated to better understand the OV101 P K-PD profile. 
The results fo r biomarker sam ples (plasma and cheek swabs ) and the anal ysis of the 
combined effect of biomarker sam ples and treatment with OV101 will be reported in a 
document se parate from the CSR.  
 
 
 
 
 
 
7.8.[ADDRESS_216161] squares mean 
change from baseline and the corresponding 95% CI will be presented for each daily dosing 
regimen and the total (all regimens) at each week. The least squares mean difference and the 
corresponding 95% CI will be presented for ea ch pairwise comparison between the [ADDRESS_216162] squares mean changes from baseline a nd corresponding 95% CIs will be plotted at 
each time point by [CONTACT_183009]. 
 
In the case of a statistically significant age group main effect ( P<0.05) in the MMRM or age 
effects deemed evident in descriptive statistics, the mean changes with 95% CI described 
above will be estimated for each age group separate ly as well as overall; this will be achieved 
by [CONTACT_183010] (age by [CONTACT_183011]) in the 
MMRM. In this case, these additional estimates and 95% CI will be tabulated and plotted. 
 
7.8.6 Other Analyses 
[IP_ADDRESS]  Demographics and Other Baseline Characteristics 
Demographic and background information variable s and subject disposition will be listed by 
[CONTACT_183012] (ie, number of subjects, mean, SD, minimum, median, and maximum) 
Graphical dis plays (eg, scatte r plots of P K concentrations versus PD res ponse) may be 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 90  
 for continuous variables. Relevant medical history/current medical conditions will be 
summarized by [CONTACT_183013]. 
 
Background information will consis t of data collected in the mo lecular FXS testing, clinical 
assessment of FXS, DSM-5 criteria for autism spectrum disorder, and IQ. 
 
The above analyses will be performed based on the randomized analysis set. 
 
[IP_ADDRESS]  Drug Treatments 
[IP_ADDRESS].1  Study Drug 
Using the safety set, duration (days) of exposure to study drug and treatment compliance will 
be listed by [CONTACT_183014]. Frequency and 
percentages for subject disposition and reasons for discontinuation of study drug will be 
presented. 
 
[IP_ADDRESS].[ADDRESS_216163] and summarized descriptively. 
 
7.8.7 Interim Analyses 
No interim statistical analysis  will be performed. Periodic inte rim blinded review of safety 
data will be performed as part of  routine pharmacovigilance activities. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 91  
 8 Data Quality Assurance 
This study will be conducted according to the risk and quality processes described in the 
relevant procedural documents.  The quality management approach  to be implemented in this 
study will be documented and will comply wi th International Council for Harmonisation 
(ICH) E6(R2) guidance on quality and risk management. 
 
Standard operating procedures are available for all activities relevant to the quality of this 
study. Designated personnel will be respons ible for implementing and maintaining quality 
assurance and quality control systems to ensure that the study is conducted and that data are 
generated, documented, and reported in compliance with the study protocol, Good Clinical 
Practice (GCP), and Good Laborat ory Practice requirements as we ll as applicable regulatory 
requirements and local laws, rules, and regulations  relating to the conduct of the clinical trial. 
 
At any time, quality assurance representatives of the sponsor and/or regulatory bodies may 
visit the unit to carry out an audit of the study in compliance with regulatory guidelines and 
sponsor policy. Such audits will require acc ess to study records,  documentation, and 
regulatory files. At all times, subject privacy  will be of utmost importance and will be 
respected. Typi[INVESTIGATOR_897], sufficient notice will be given to the investigator to prepare for the visit. 
 
In the event of an audit or inspection, the invest igator (and institution) must agree to grant the 
auditor(s) and inspector(s) direct access to all relevant documents and to allocate their time 
and the time of their staff to discuss any finding s or relevant issues. The investigator must 
notify the sponsor of any regulatory authority inspections and forward copi[INVESTIGATOR_182969]. 
 
Electronic data systems will be in accordance with applicable aspects of US Title 21 Code of 
Federal Regulations (CFR) Part 11, ICH Guidelines, GCP, local laws and legislation, and the 
Health Insurance Portability and Accountability Act. 
 
Responsibility for the accuracy, completeness, a nd reliability of the study data presented to 
the sponsor lies with the inve stigator generating the data. 
 
8.1 Data Management 
As part of the responsibilities assumed by [CONTACT_183015], the investigator agrees to 
maintain adequate case histories for the subjects  treated as part of the research under this 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 92  
 protocol. The investigator agrees to maintain  accurate eCRFs and source documentation as 
part of the case histories. These source docum ents may include documents including (but not 
restricted to) the following: laboratory reports , questionnaire results,  sleep diaries, and 
computerized or otherwise automated assessments. 
 
Investigative site personnel will ente r subject data into Medidata RAVE® (the eCRF EDC 
program). The analysis data sets will be a co mbination of these data  and data from other 
sources (eg, laboratory data). 
 
Clinical data management will be performed in  accordance with applicable sponsor standards 
and data cleaning procedures to ensure the integrity of the data, eg, removing errors and 
inconsistencies in the data. There will be 100% source data verification. Adverse event terms 
will be coded using MedDRA, an internal validated medical dictionary, and concomitant medications will be coded using the World Health Organization Drug Dictionary. 
 
After database lock, each study site will receive a CDROM containing all of their 
site-specific eCRF data as entered into the EDC system for the study, including full 
discrepancy and audit history. Additionally, a CDROM copy of all of the study site’s data 
from the study will be created and sent to the sponsor for storage. [COMPANY_003] will maintain a 
duplicate CDROM copy for their records. In all case s, subject initials will not be collected or 
transmitted to the sponsor. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216164](s) 
Federal regulations and ICH guidelines require that approval be obtained from an IRB before 
participation of human subjects in research studies. Before study onset, the protocol, 
informed consent and assent, advertisements to be used for the recruitment of study subjects, 
and any other written information regarding this study to be provided to the subject or the 
subject’s LAR/caregiver must be approved by [CONTACT_1201]. Documentation of all IRB approvals 
and of IRB compliance with ICH harmonised tripartite guideline E6(R2): GCP will be 
maintained by [CONTACT_135780]. 
 
All IRB approvals should be signed by [CONTACT_183016], the clinical protocol by [CONTACT_11777], all approved 
materials, and the date approval or a favorable opi[INVESTIGATOR_11744]. 
 
The investigator is responsible for providing wr itten summaries of the progress and status of 
the study at intervals not exceeding [ADDRESS_216165] (or from the LAR/caregiver of a minor or adult of diminished mental capacity, as applicable) befo re the subject enters the study or any unusual 
or nonroutine procedure that involves risk to the subject is performed. For minors or adults of diminished mental capacity, an assent document will be presented and assent obtained before 
the subject participates in any study procedure. Informed consent and assent template 
documents may be provided by [CONTACT_183017]. If any institution-specific 
modifications to study-related pr ocedures are proposed or made by [CONTACT_779], the consent and 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 94  
 There will be separate o ptional consents and assents fo r metabolomic anal ysis as well as for 
cheek swab sam pling and subse quent processin g for microbiome anal ysis. Those sub jects fo r 
whom o ptional consents are no t provided will still be eligible for the main stud y. assent should be reviewed by [CONTACT_183018]. 
Once reviewed, the consent and assent will be s ubmitted by [CONTACT_183019]. If the informed consent form (ICF) is 
revised during the course of the study, all ac tive participating subjects and LAR/caregivers 
(as applicable) must si gn the revised forms.   
 
 
 
 
Before recruitment and enrollment, each prospective subject’s LAR/caregiver and subject (as 
applicable) will be given a full explanation of the study and will be allowed to read the 
approved ICF/assent. Once the investigator is  assured that the LAR/ caregiver and subject 
understand the implications of participating in the study, the LAR/caregiver and subject will 
be asked to give consent/assent to partic ipate in the study by [CONTACT_2960]/approving the 
ICF/assent. 
 
The investigator shall retain the signed original  ICFs/assents and give copi[INVESTIGATOR_55618]/caregivers and subjects, as applicable. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 95  
 10 Investigator’s Obligations 
The following administrative items are meant to guide the investigator in the conduct of the 
study but may be subject to change based on industry and government standard operating procedures, working practice documents, or guid elines. Changes will be reported to the IRB 
but will not result in protocol amendments. 
 
10.[ADDRESS_216166] (or the subject’s legal guardian or LAR/caregiver), except as 
necessary for monitoring and a uditing by [CONTACT_456], its designee, the US Food and Drug 
Administration (FDA), or the IRB. 
 
The investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performanc e of the study any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the study. Prior written agreement from the sponsor or its designee must be obtained for the 
disclosure of any said confidential information to other parties. 
 
10.[ADDRESS_216167]’s disease. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 96  
 10.3 Investigator Documentation 
Prior to beginning the study, the investigator will be asked to comply with ICH E6(R2) 8.2 
and Title 21 of the CFR by [CONTACT_11778], including but not limited to the 
following: 
 
 IRB approval. 
 Original investigator-signed investigator agreement page of the protocol. 
 Form FDA 1572, fully executed, and all updates on a new fully executed Form 
FDA 1572. 
 Curriculum vitae for the inve stigator and each subinvestigator listed on Form 
FDA 1572. 
 Financial disclosure information to allow th e sponsor to submit complete and accurate 
certification or disclosure statements required under [ADDRESS_216168] provide to the sponsor a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and 
for 1 year after the completion of the study. 
 IRB-approved informed consent, samples of site advertisements for recruitment for 
this study, and any other written information regarding this study that is to be provided 
to the subject or legal guardian. 
 Laboratory certifications and normal ranges for any local laboratories used by [CONTACT_779], 
in accordance with [ADDRESS_216169] 
The investigator agrees that the study will be  conducted according to the principles of ICH 
E6(R2). The investigator will conduct all aspects of this study in accordance with all 
national, state, and local laws or regulations . Study information from this protocol will be 
posted on publicly available clinical trial registers before the enrollment of subjects begins. 
 
10.[ADDRESS_216170] the study as outlined in this protocol in accordance with 
ICH E6(R2) and all applicable  guidelines and regulations. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 97  
 10.6 Adverse Events and Study Report Requirements 
By [CONTACT_183020]/or IRB according to the timeline and method  outlined in the protocol. In addition, the 
investigator agrees to subm it annual reports to the study site IRB as appropriate. 
 
10.7 Investigator’s Final Report 
Upon completion of the study, the investigator, where applicable, should inform the 
institution; the investigator/institution should provide the IRB with a summary of the study’s 
outcome and the sponsor and regulatory aut hority(ies) with any reports required. 
 
10.[ADDRESS_216171]. These documents should be retained for a longer period, howeve r, if required by [CONTACT_107245] . It is the responsibility of the sponsor to 
inform the investigator/institutio n as to when these documents no longer need to be retained. 
 
10.9 Publications 
After completion of the study, the data may be considered for reporting at a scientific 
meeting or for publication in a scientific journal. In these cases, the sponsor will be 
responsible for these activities and will work with the investigators to determine how the 
manuscript is written and edited, the number and order of authors, the publication to which it 
will be submitted, and other related issues. Th e sponsor has final approval authority over all 
such issues. 
 
The data are the property of the sponsor and ca nnot be published without prior authorization 
from the sponsor, but data and publication thereof will not be unduly withheld. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216172] copi[INVESTIGATOR_21688]. 

Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216173] be submitted in writing to the investigator’s IRB 
for approval before subjects can be enrolled into an amended protocol. 
 
11.2.[ADDRESS_216174]’s source documentation any deviation from  the approved protocol. The investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study 
subjects without prior IRB approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments 
should be submitted to the IRB for review and approval, to the sponsor for agreement, and to regulatory authorities, if required. 
 
A deviation from the protocol is an unintended or unanticipated departure from the procedures or processes approved by [CONTACT_183021]. A significant deviation occurs when there is nonadherence to the protocol by [CONTACT_21768] a significant additional risk to the subject. Significant 
deviations can include nonadherence to inclusi on or exclusion criteria or nonadherence to 
FDA regulations or ICH GCP guidelines and w ill lead to the subject being withdrawn from 
the study (Section 4.2). 
 
Protocol deviations will be documented by [CONTACT_135786]. Principal investigators will be notified of deviations in writing by [CONTACT_36102]. The IRB should be notified of al l protocol deviations in a timely manner. 
 
11.[ADDRESS_216175] visit 
(includes follow-up visit). 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 100  
 11.4 Final Report 
Whether the study is completed or prematurely terminated, the sponsor will ensure that the 
CSRs are prepared and provided to the regulat ory agency(ies) as required by [CONTACT_40006](s). The sponsor will also ensure that the CSRs in marketing 
applications meet the standards of the ICH ha rmonised tripartite guideline E3: Structure and 
content of clinical study reports. 
 
Where required by [CONTACT_31851], an investigator signatory will be 
identified for approval of the CSR. The investigator will be provided reasonable access to 
statistical tables, figures, and relevant reports and will have the opportunity to review the 
complete study results. 
 
Upon completion of the CSR, the sponsor will provide the investigator with the full summary 
of the study results. The investigator is enco uraged to share the summary results with the 
study subjects and their LAR/caregivers, as appropriate. The study results will be posted on publicly available clinical trial registers. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216176]. Am J Me nt Defic. 1985;89(5):492-502. 
 
Bakker CE, Verheij C., Willemsen R, et al; Dutch-Belgian Fragile X Consortium. Fmr1 
knockout mice: a model to study fragile X mental retardation. Cell. 1994;78(1):23-33. 
 
Bhakar AL, Dölen G, Bear MF. The pathophysiology of fragile X (and what it teaches us 
about synapses). Annu Rev Neurosci. 2012;35:417-43. 
 
Bodfish JW, Symons FJ, Parker  DE, et al. Varieties of repetitive behavior in autism: 
comparisons to mental retardation. J Autism Dev Disord. 2000;30(3):237-43. 
 
Braat S, Kooy RF. Insights into GABA Aergic system deficits in fragile X syndrome lead to 
clinical trials. Neuropharm acology 2015;88: 48-54. 
 
Cogram P, Deacon RJ, During MJ, et al. Gaboxadol normalizes be havioral abnormalities in a 
mouse model of fragile X syndrome. Poster pr esented at: 18th International Fragile X and 
Related Neurodevelopmental Disorders Workshop ; [ADDRESS_216177] 12-16; Saint-Alexis-des-Monts, 
Quebec. 
 
Crawford DC, Acuña JM, Sherman SL. FMR1 and the fragile X syndrome: human genome 
epi[INVESTIGATOR_182970]. Genet Med. 2001;3(5):359-71. 
 
D’Hulst C, Kooy RF. The GABA A receptor: a novel target for treatment of fragile X? Trends 
Neurosci. 2007;30(8):425-31. 
 
Esbensen AJ, Rojahn J, Aman MG, et al. Reliability and validity of an assessment instrument 
for anxiety, depression, and mood among indivi duals with mental retardation. J Autism Dev 
Disord. 2003;33(6):617-29. 
 
Ethridge LE, White SP, Mosconi MW, et al. Reduced habituation of auditory evoked 
potentials indicate cortical hyper-excitabilit y in fragile X syndrome. Transl Psychiatry. 
2016;6:e787. 
 
Fernández E, Rajan N, Bagni C. The FMRP regu lon: from targets to disease convergence. 
Front Neurosci. 2013;7:191. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 102  
 Gantois I, Vandesompele J, Speleman F, et al. Expression profiling suggests underexpression 
of the GABA A receptor subunit δ in the fragile X knockout mouse model. Neurobiol Dis.  
2006;21(2):346-57. 
 
Gould EL, Loesch DZ, Martin MJ, et al. Melatoni n profiles and sleep characteristics in boys 
with fragile X syndrome: a preliminary study. Am J Med Genet. 2000;95(4):307-15. 
 
Hagerman R, Hoem G, Hagerman P. Fragile X and autism: intertwined at the molecular level 
leading to targeted treatments. Mol Autism. 2010;1:12. 
 
Hagerman RJ. The physical and behavior phenotype. In: Hagerman  RJ, Hagerman PJ, 
editors. Fragile X syndrome: diagnosis, treatment, and research. 3rd ed. Baltimore: Johns 
Hopkins University Press; 2002. p 3-109. 
 
Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X 
syndrome. Pediatrics . 2009;123(1):378-90. 
 
Hall SS, Lightbody AA, Reiss AL. Compulsive, self-injurious, and autistic behavior in 
children and adolescents with fragile X synd rome. Am J Ment Retard. 2008;113(1):44-53. 
 
Harris SW, Hessl D, Goodlin-Jones B, et al. Autism profiles of males with fragile X 
syndrome. Am J Ment Re tard. 2008;113(6):427-38. 
 
Kenneson A, Zhang F, Hagedorn CH, et al. Reduced FMRP and increased FMR1 
transcription is proportionally associated with  CGG repeat number in intermediate-length and 
premutation carriers. Hum Mol Genet. 2001;10(14):1449-54. 
 
Knox A, Schneider A, Ab ucayan F, et al. Feasib ility, reliability, and clinical validity of the 
Test of Attentional Performance for Children (KiTAP) in fragile X syndrome (FXS). J 
Neurodev Disord. 2012;4:2. 
 
Kristensen BW, Noraberg J, Zimmer J. The GABA A receptor agonist THIP is neuroprotective 
in organotypic hippocampal slice cultures. Brain Res. 2003;973(2):303-6. 
 
Kronk R, Bishop EE, Raspa M, et al. Prevalence, nature, and correlates of sleep problems 
among children with fragile X syndrome based on a large scale parent survey. Sleep. 
2010;33(5):679-87. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 103  
 Malow BA, Connolly HV, Weiss SK, et al. The Pediatric Sleep Clinical Global Impressions 
Scale–a new tool to measure pediatric insomnia in autism spectrum disorders. J Dev Behav 
Pediatr. 2016;37(5):370-6. 
 
Martin BS, Corbin JG, Huntsman, MM. Deficient tonic GABAergic conductance and 
synaptic balance in the fragile X syndrome amygdala. J Neurophysiol. 2014;112(4):890-902. 
 
Medrihan L, Ferrea E, Greco B, et al. Asynchronous GABA release is a key determinant of tonic inhibition and controls neuronal excitability: a study in the synapsin II
-/- mouse. Cereb 
Cortex. 2015;25(10):3356-68. 
 
Olmos-Serrano JL, Corbin JG, Burns MP. The GABA A receptor agonist THIP ameliorates 
specific behavioral deficits in the mouse model of fragile X syndrome. Dev Neurosci. 
2011;33(5):395-403. 
 
Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, et al. Defective GABAergic 
neurotransmission and pharmacological rescue of  neuronal hyperexcitability in the amygdala 
in a mouse model of fragile X syndrome. J Neurosci. 2010;30(29):9929-38. 
 
Ovid Therapeutics Inc. Gaboxadol (OV101). Investigator’s brochure, 2nd ed. [LOCATION_001] 
(NY); 2017. [ADDRESS_216178] en's Sleep Habits Questionnaire (CSHQ): 
psychometric properties of a survey instrument for school-aged children. Sleep. 
2000;23(8):1-9. 
 
Randolph C, Tierney MC, Mohr E, et al. The Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 
1998;20(3):310-9. 
 
Richdale AL. A descriptive analysis of sleep be haviour in children with fragile X. J Intellect 
Dev Disabil. 2003;28(2):135-44. 
 
Roth T, Lines C, Vandormael K, et al. Effect  of gaboxadol on patient-reported measures of 
sleep and waking function in patients with primary insomnia: results from two randomized, 
controlled, 3-month studies. J Clin Sleep Med. 2010;6(1):30-9. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-[ADDRESS_216179]. 2012;42(7):1377-92. 
 
Sun Y, Wu Z, Kong S, et al. Regulation of epi[INVESTIGATOR_182971] A receptors. Mol Brain. 2013;6:21.  
 
Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of FMR1 mRNA in carrier males: 
a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet. 
2000;66(1):6-15. 
 
Varni JW, Sherman SA, Burwinkle TM, et al. The PedsQL™ Family Impact Module: 
preliminary reliability and validity. Health Qual Life Outcomes. 2004;2:55. 
 
Wheeler AC, Raspa M, Bishop E, et al. Aggressi on in fragile X syndrome. J Intellect Disabil 
Res. 2016;60(2):113-25. 
 
Whissell PD, Rosenzweig S, Lecker I, et al. γ-Aminobutyric acid type A receptors that 
contain the δ subunit promote memory and neurogenesis in the dentate gyrus. Ann Neurol. 
2013;74(4):611-21. 
 
Zhang J, Fang Z, Jud C, et al. Fragile X- related proteins regulate mammalian circadian 
behavioral rhythms. Am J Hum Genet. 2008;83(1):43-52. 
Ovid Therapeutics Inc. 
Protocol: OV101-17-001 Version 1.2 OV101 
27 Mar 2019 
Page 105  
 13 Appendix (Israel Site-S pecific Instructions) 
The SB-5, which is to be conducted at screening,  is not available in Hebrew. Therefore, for 
the site in Israel, alternative IQ assessments such as the Wechsler Intelligence Scale for 
Children (WISC), Wechsler Preschool and Primary Scale of Inte lligence (WPPSI), or 
Kaufman Assessment Battery for Children (KABC)  may be used. It is important that the 
alternative IQ test yields a full scale IQ (with nonverbal and verbal scores). For example, the 
Leiter International Performance Scale is a n onverbal intelligence test and therefore, would 
not be an appropriate substitute of the SB-5. 
 
An equivalent previously documented IQ measurement conducted within [ADDRESS_216180] as having an IQ less than 75. 